Collaborative Testing Services, Inc
FORENSIC TESTING PROGRAM

P.O. Box 650820
Sterling, VA 20165-0820
e-mail: forensics@cts-interlab.com
Telephone: +1-571-434-1925
Web site: www.cts-forensics.com

# Urine Drug Analysis
# Test No. 22-5671 Summary Report

Each sample set contained urine samples from three individual cases with unique scenarios. Participants were requested to analyze the urine samples and report the presence of any drugs/metabolites, any quantitative data obtained (including uncertainty), and the methods used. Data were returned from 118 participants and are compiled into the following tables:



This report contains the data received from the participants in this test. Since these participants are located in many countries around the world, and it is their option how the samples are to be used (e.g., training exercise, known or blind proficiency testing, research and development of new techniques, etc.), the results compiled in the Summary Report are not intended to be an overview of the quality of work performed in the profession and cannot be interpreted as such. The Summary Comments are included for the benefit of participants to assist with maintaining or enhancing the quality of their results. These comments are not intended to reflect the general state of the art within the profession.

Participant results are reported using a randomly assigned "WebCode". This code maintains participant's anonymity, provides linking of the various report sections, and will change with every report.

# Manufacturer's Information

The sample sets contained urine samples from three individual cases with unique scenarios. Each case sample consisted of one specimen bottle containing 50mL of human urine. Participants were requested to analyze the urine samples and report the presence of any drugs/metabolites, any quantitative data obtained (including uncertainty), and the methods used.

SAMPLE PREPARATION: The urine used in this test was from the same lot, which tested negative for a variety of common drugs and controlled substances. A stock solution of each chosen drug was used to spike each item. Items were prepared at separate times with different glassware using the following procedure.

ITEMS 1, 2, and 3 (PREPARATION): Sample preparation consisted of adding a predetermined amount of drug stock solution to a beaker containing human urine, where the equivalent of 2% w/v sodium fluoride was added and then stirred. A 50mL aliquot of the mixture was then transferred into each of the pre-labeled specimen bottles. All bottles were stored in a refrigerator immediately after production and remained there until the sample sets were prepared.

SAMPLE SET ASSEMBLY: A sample set was created by packing Items 1, 2, and 3 together. Each sample set was placed into a Department of Transportation regulated shipping container and returned to the refrigerator until shipment.

VERIFICATION: The laboratories that conducted predistribution testing reported results for all three items that correlated with production data and consensus responses.

| Item 1 Drug (Concentration) | Item 2 Drug (Concentration) | Item 3 Drug (Concentration) |
|---|---|---|
| Morphine (2,400 ng/mL) | Fentanyl (150 ng/mL) | Amphetamine (600 ng/mL) |
| Oxycodone (800 ng/mL) | Norfentanyl (1,000 ng/mL) | |
| 6-acetylmorphine (200 ng/mL) | | |

Please note that the preparation concentration is the value used for calculations during the test preparation phase and may not necessarily represent the final concentration of the samples. It is advised to wait for the Grand Mean statistics available in the Summary and Individual Reports before evaluating performance.

 

# Summary Comments

This test was designed to allow participants to assess their proficiency in the examination for the presence and concentration of drugs and/or metabolites in urine. The sample sets provided to participants contained urine samples from three individual cases with unique scenarios. Each case sample consisted of one specimen bottle containing 50mL of human urine. Participants were requested to analyze the urine samples and report the presence of any drugs/metabolites, any quantitative data obtained (including uncertainty), and the methods used. (Refer to the Manufacturer's Information for preparation details)

There were 118 participants who reported screening results for Item 1. Most commonly reported was the presence of Opiates/Opioids by 79 participants; 77 reported the presence of Oxycodone; 43 reported the presence of Morphine, and 47 reported the presence of 6-acetylmorhine/Monoacetylmorphine. Of the 108 participants who reported confirmatory results for Item 1, 102 (94.4%) reported the presence of Morphine, 100 (92.6%) reported the presence of Oxycodone, and 102 (94.4%) reported the presence of 6-acetylmorphine.

There were 117 participants who reported screening results for Item 2. Most commonly reported was the presence of Fentanyl by 81 participants, and 35 reported the presence of Norfentanyl. Of the 103 participants who reported confirmatory results for Item 2, 90 (87%) reported the presence of Fentanyl, and 55 (53%) reported the presence of Norfentanyl.

There were 116 participants who reported screening results for Item 3 with 87 reporting the presence of Amphetamine. Of the 103 participants who reported confirmatory results for Item 3, 95 (92%) reported the presence of Amphetamine.

For all three items, immunoassay was the most common screening method and GC/MS was the most common confirmatory method used to analyze the samples.

If a participant indicated that the confirmatory quantitative result was a single determination and it was reported in ng/mL, the conclusive quantitative result was included in the raw data table. Due to the small number of participants who reported quantitative information, no grand mean statistics were calculated or determinations regarding extreme data made for any of the analytes in the three items.

 

# Screening Results - Item 1

TABLE 1A

Item Scenario:

A 26-year-old male was subject to a routine drug test as part of a drug and alcohol rehabilitation program. A urine sample was collected for analysis.

Item Contents and Preparation Concentration: Morphine (2,400 ng/mL)
Oxycodone: (800 ng/mL)
6-acetylmorphine: (200 ng/mL)

| WebCode | Screening Results |
|---|---|
| 2JBUGR | common opioids |
| 3743CY | 6-monoacetylmorphine<br>Morphine<br>Oxycodone |
| 3AZRVQ | Opioids --> morphine, oxycodone, 6-monoacetyl-morphine |
| 3RJMAY | Opiates, Oxycodone |
| 43TPZP | No drugs detected utilizing screening methods. |
| 4AFBFN | morphine<br>oxycodone<br>6-MAM |
| 4AVRBG | Morphine<br>6-monoacetylmorphine<br>oxycodone |
| 4AYEMP | Opioids: morphine, oxycodone, 6-monoacetyl-morphine (6-MAM) |
| 4ET9KQ | Opioids |
| 4YW39M | Opiates, Morphine, Oxycodone |
| 6CGVE9 | 6-monoacetylmorphine<br>morphine<br>oxycodone |
| 6M2633 | opiates |
| 6XECWG | Opiates, oxycodone, 6-acetylmorphine |
| 76V339 | Opiates<br>6-Acetyl-Morphine<br>Oxycodone |
| 7AN9EP | Opiates |
| 7E32DV | No drugs detected utilizing screening methods. |
| 7TJU33 | Opiate<br>Oxycodone |

# TABLE 1A: Screening Results - Item 1

| WebCode | Screening Results |
|---|---|
| 83PYUJ | 6-monoacetyl morphine<br>morphine<br>oxycodone |
| 8J9TG2 | opiates, oxycodone |
| 8WWUYT | Opiates (ELISA)<br>Oxycodone/Oxymorphone (ELISA) |
| 96RG6J | opioids |
| 98BFDM | Opiates |
| 9K27GY | Methamphetamine<br>Opiates<br>Oxycodone/Oxymorphone<br>Amphetamine |
| 9N397Z | Opiates<br>Oxycodone |
| 9PUCTF | Opiates (class); 6-Monoacetylmorphine (Heroin metabolite), Morphine, Oxycodone. |
| A4APRT | Morphine, 6-O-Monoacetylmorphine, Oxycodone |
| A7X4G3 | POSITIVE OPIATES |
| A87HGG | 6 AM- 6 Acetyl Morphine<br>OPI- Opiates<br>OXY- Oxycodone |
| AF6VNC | Opiates |
| AFYTRC | Barbiturates<br>Cannabinoids<br>Opiates<br>Oxycodone |
| ALQUEK | Opioids |
| AMM82D | Monoacetylmorphine (6-MAM), morphine, oxycodone |
| AUKY62 | Morphine<br>6-acetylmorphine<br>Oxycodone |
| B2Y873 | opiates |
| BDRNV4 | Opiates<br>6-Acetyl-Morphine<br>Oxycodone |

# TABLE 1A: Screening Results - Item 1

| WebCode | Screening Results |
|---|---|
| BMJ8CX | Opiates, oxycodone |
| BP6NUH | Opioids class |
| BT9L24 | Opiates |
| C6TL8W | Opiate<br>Oxycodone |
| CB3NBD | Opiate<br>Morphine<br>Oxycodone<br>6-Monoacetylmorphine (Heroin Metabolite) |
| CDMTP3 | Opiates |
| CT4N6Y | Morphine<br>O6-Monoacetylmorphine<br>Oxycodone |
| D6DJZN | No drugs detected utilizing screening methods. |
| DJTMJX | Morphine, Oxycodone, 6-Monoacetylmorphine |
| EJPEUB | oxycodone, morphine, 6-MAM |
| EMPQQB | morphine<br>oxycodone<br>6-monoacetylmorphine |
| EPD7WD | 6AM- 6 Acetyl Morphine<br>OPI- Opiates<br>OXY- Oxycodone |
| EWB2UB | Opiates. |
| F6LKQF | Opiates |
| FF8JPX | Opiates |
| FJ7VLX | Opiates (Morphine, Monoacetylmorphine, Oxycodone ) |
| FXK3FA | Opiates, Oxycodone |
| G3QAED | common opioids |
| GFG7GB | opioids |
| GRAEFD | 1. Opiates<br>2. Oxycodone/ Oxymorphone |

 

# TABLE 1A: Screening Results - Item 1

| WebCode | Screening Results |
|---|---|
| GUKA4Q | Opiates/Oxycodone/6-Acetylmorphine<br>Benzodiazepines<br>Zolpidem |
| GZLQ96 | opiates, oxycodone, 6-acetylmorphine |
| GZP7MQ | morphine<br>oxycodone<br>6-monoacetylmorphine |
| HBLHEA | 6AM- 6 acetyl morphine<br>OPI- Opiates<br>OXY- Oxycodone |
| HPHQEX | Opiate positive EMIT |
| HQF42P | Opiates, oxycodone/oxymorphone |
| JQ9FTB | Opiates |
| KNE3R4 | No drugs detected utilizing screening methods. |
| KVY39G | Opiates<br>Oxycodone |
| L2447P | Opioids: Morphine, oxycodone and 6-monoacetylmorphine were detected |
| LDU3QZ | Opiates<br>Oxycodone |
| LDZAZM | oxycodone, opiates |
| LERDM3 | Opiates |
| LHPWN2 | opiates |
| LQMJMT | 6-acetylmorphine<br>morphine<br>oxycodone |
| LX6WJ7 | Oxycodone |
| LYVVX6 | Opiates |
| M4Q32Y | Drug class positive: 6-Monoacetylmorphine, Opiates, Oxycodone.<br>Drugs detected present: 6-MAM, Morphine, Oxycodone |
| M6VYZ9 | Monoacetylmorphine<br>Morphine<br>Oxycodone |
| M9UBV9 | Oxycodone 1, Oxycodone2, Opiates, Opioids |

 

# TABLE 1A: Screening Results - Item 1

| WebCode | Screening Results |
|---|---|
| MGR2KP | Morphine, 6-Monoacethylmorphine, Oxycodone |
| MNWK33 | Opiate - Morphine, 6-monoacetylmorphine, Oxycodone |
| MU2CDL | Opiate, Oxycodone |
| MUJMT7 | opioids |
| NK7TCH | Morphine<br>Oxycodone |
| NYNLZP | Opiates |
| P7KZZG | Morphine<br>Oxycodone |
| PG4AQV | Opiates |
| PXQTHB | ELISA Opiates, ELISA Oxycodone |
| Q4EUZ2 | Morphine, Oxycodone, 6-monoacetyl-morphine |
| Q63FMW | Morphine<br>Oxycodone |
| QKXQGU | 6-monoacetylmorphine, acetaminophen, benzoylecgonine, morphine/hydromorphone, oxycodone |
| QQJTDY | Opiates<br>Oxycodone |
| QXKXCA | 6-monoacetylmorphine, morphine, oxycodone |
| RDB8PZ | 6 AM- 6 Acetyl Morphine<br>OPI- Opiates<br>OXY- Oxycodone |
| RQLHHW | Opiates |
| RYRJG2 | morphine and 6-monoacetylmorphine and oxycodone and heroin . |
| TG94UK | Opiate |
| TLRYZX | morphine<br>oxycodone<br>6-monoacetyl morphine |
| TMFE6Z | 6AM- 6 Acetyl-Morphine<br>OPI- Opiates<br>OXY- Oxycodone |
| TNT2PY | Opiates |

# TABLE 1A: Screening Results - Item 1

| WebCode | Screening Results |
|---|---|
| TQFMCV | Opiates |
| TRTAUA | Morphine, 6-acetylmorphine, Oxycodone |
| TUGNHJ | morphine, 6-acetylmorphine, oxicodone |
| UR8YTF | Opiates |
| UTH8CZ | 6-acetylmorphine, morphine, codeine, oxycodone |
| UY9DEG | Opiates<br>Oxycodone<br>6-mam |
| V2AXJT | morphine<br>oxycodone<br>6-acetylmorphine |
| VMBUCG | No drugs detected utilizing screening methods. |
| VV46MC | Opiates, oxycodone/oxymorphone, amphetamine |
| WWVHMA | Morphine<br>Oxycodone |
| X4AVWT | Opiate Class |
| XCKWHT | Opiates (Morphine and oxycodone) |
| XHU9GF | Morphine<br>6-monoacetylmorphine (6MAM)<br>Oxycodone |
| XTEFHP | 6 Mono acetylmorphine<br>Morphine<br>Oxycodone |
| XZPYEU | morphine, 6-monoacetyl-morphine, oxycodone |
| YCZT6D | No drugs detected utilizing screening methods. |
| YNDT4R | opioids |
| YQGNMV | opioids (morphine, 6-monoacetylmorphine) and oxycodone |
| Z4ZQF7 | Opiates and Oxycodone/Oxymorphone |
| ZBKTMA | Opiates, Oxycodone |
| ZGR6XN | Opiates |
| ZVQ26T | opiates |

 

| Screening Response Summary for Item 1 | Participants: 118 |
|---|---|
| Opiates/Opioids: | 79 |
| Oxycodone: | 77 |
| 6-acetylmorphine/Monoacetylmorphine/6-MAM | 48 |
| Morphine | 43 |
| Other drugs/metabolites detected: | 17 |
| No drugs/metabolites detected Utilizing Screening Methods: | 6 |

Total number of screening responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

# Confirmatory Results - Item 1

TABLE 1B

Item Scenario:

A 26-year-old male was subject to a routine drug test as part of a drug and alcohol rehabilitation program. A urine sample was collected for analysis.

Item Contents and Preparation Concentration: Morphine (2,400 ng/mL)
Oxycodone: (800 ng/mL)
6-acetylmorphine: (200 ng/mL)

***What drugs/metabolites were detected in Item 1?***

| WebCode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---|---|---|---|---|---|
| 2JBUGR | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetyl-morphine | ✓ | | | |
| 3743CY | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| 3AZRVQ | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetyl-morphine | ✓ | | | |
| 3RJMAY | morphine | | 2,514 ng/mL | 85 | ng/mL |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine | ✓ | | | |
| 43TPZP | No drugs/metabolites detected utilizing confirmatory methods. | | | | |
| 4AFBFN | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-MAM | ✓ | | | |
| 4AVRBG | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| 4AYEMP | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetyl-morphine | ✓ | | | |
| 4ET9KQ | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetyl morphine | ✓ | | | |

# TABLE 1B: Confirmatory Results - Item 1

| ***What drugs/metabolites were detected in Item 1?*** | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| 4YW39M | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine | ✓ | | | |
| 6CGVE9 | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetylmorpine | ✓ | | | |
| 6M2633 | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| 76V339 | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine | | >200 | | ng/mL |
| 7E32DV | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Acetylmorphine | ✓ | | | |
| 7TJU33 | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine | ✓ | | | |
| 83PYUJ | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetyl morphine | ✓ | | | |
| 8J9TG2 | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| 8WWUYT | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Acetylmorphine | ✓ | | | |
| 96RG6J | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetyl-morphine | ✓ | | | |
| 98BFDM | Morphine | | 2203 | | ng/mL |
| | Oxycodone | ✓ | | | |
| | 6-MAM | | 160 | | ng/mL |

# TABLE 1B: Confirmatory Results - Item 1

| ***What drugs/metabolites were detected in Item 1?*** | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| 9K27GY | Ephedrine/Pseudoephedrine | ✓ | | | |
| 9N397Z | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| 9PUCTF | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine (Heroin metabolite) | ✓ | | | |
| A4APRT | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-O-Monoacetylmorphine | ✓ | | | |
| A7X4G3 | Morphine | ✓ | | | |
| | oxicodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| AF6VNC | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| AFYTRC | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine | ✓ | | | |
| ALQUEK | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine | ✓ | | | |
| AMM82D | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | Monoacetylmorphine (6-MAM) | ✓ | | | |
| AUKY62 | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-acetylmorphine | ✓ | | | |
| B2Y873 | morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine | ✓ | | | |

# TABLE 1B: Confirmatory Results - Item 1

| ***What drugs/metabolites were detected in Item 1?*** | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| BDRNV4 | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine | | 190.02 | 19.00 | ng/mL |
| BMJ8CX | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| BP6NUH | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetyl morphine (6-MAM) | ✓ | | | |
| BT9L24 | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine | ✓ | | | |
| C6TL8W | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine | ✓ | | | |
| CB3NBD | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine (Heroin metabolite) | ✓ | | | |
| CDMTP3 | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| CT4N6Y | Morphine | | 2404 | | ng/ml |
| | Oxycodone | ✓ | | | |
| | O6-Monoacetylmorphine | | 178 | | ng/ml |
| D6DJZN | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Acetylmorphine | ✓ | | | |
| DJTMJX | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Acetylmorphine | ✓ | | | |

# TABLE 1B: Confirmatory Results - Item 1

| ***What drugs/metabolites were detected in Item 1?*** | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| EJPEUB | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-MAM | ✓ | | | |
| EMPQQB | morpine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monacetylmorphone | ✓ | | | |
| EWB2UB | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| F6LKQF | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | Monoacetymorphine | ✓ | | | |
| FF8JPX | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine | ✓ | | | |
| FJ7VLX | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | Monoacetylmorphine | ✓ | | | |
| FXK3FA | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Acetylmorphine | ✓ | | | |
| G3QAED | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-MAM (6-monoacetyl-morphine) | ✓ | | | |
| GFG7GB | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetyl morphine | ✓ | | | |
| GRAEFD | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine | ✓ | | | |
| GUKA4Q | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine | ✓ | | | |

# TABLE 1B: Confirmatory Results - Item 1

| ***What drugs/metabolites were detected in Item 1?*** | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| GZP7MQ | morphine | | 2,5 | | mg/l |
| | oxycodone | | 0,68 | | mg/l |
| | 6-monoacetylmorphine | | 0,15 | | mg/l |
| HPHQEX | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| HQF42P | Oxycodone | ✓ | | | |
| | 6-Acetylmorphine (6-MAM) | ✓ | | | |
| JQ9FTB | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-acetylmorphine | ✓ | | | |
| KNE3R4 | Morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | monoacetylmorphine | ✓ | | | |
| KVY39G | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-monoacetylmorphine (6MAM) | ✓ | | | |
| L2447P | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| LDU3QZ | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine | ✓ | | | |
| LDZAZM | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-acetylmorphine | ✓ | | | |
| LERDM3 | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine (Heroin Metabolite) | ✓ | | | |
| LHPWN2 | morphine | ✓ | | | |
| | oxycodone | | | | |
| | (6-acetylmorphine) | ✓ | | | |

 

# TABLE 1B: Confirmatory Results - Item 1

| ***What drugs/metabolites were detected in Item 1?*** | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| LQMJMT | morphine | ✓ | | | |
| | oxycodone | | | | |
| | 6-acetylmorphine | ✓ | | | |
| LYVVX6 | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| M4Q32Y | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-MAM | ✓ | | | |
| M6VYZ9 | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | Monoacetylmorphine | ✓ | | | |
| M9UBV9 | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-MonoAcetyl Morphine | ✓ | | | |
| MGR2KP | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacethylmorphine | ✓ | | | |
| MNWK33 | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| MU2CDL | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine | ✓ | | | |
| MUJMT7 | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetyl Morphine | ✓ | | | |
| NK7TCH | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| NYNLZP | Morphine | ✓ | | | |
| | 6-Monoacethylmorphine | ✓ | | | |
| P7KZZG | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |

# TABLE 1B: Confirmatory Results - Item 1

| ***What drugs/metabolites were detected in Item 1?*** | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| PG4AQV | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine (6-MAM) | ✓ | | | |
| PXQTHB | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Acetylmorphine | ✓ | | | |
| Q4EUZ2 | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-monoacetyl-morphine | ✓ | | | |
| Q63FMW | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | | | | |
| QKXQGU | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| QQJTDY | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine | ✓ | | | |
| QXKXCA | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| RQLHHW | Morphine | | 2194 | | ng/mL |
| | 6 monoacetylmorphine | | 183 | | ng/mL |
| RYRJG2 | 6-monoacetylmorphine | ✓ | | | |
| TG94UK | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Monoacetylmorphine | ✓ | | | |
| TLRYZX | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetyl morphine | ✓ | | | |
| TNT2PY | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-acetylmorphine | ✓ | | | |

# TABLE 1B: Confirmatory Results - Item 1

| ***What drugs/metabolites were detected in Item 1?*** | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| TQFMCV | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6 monoacetylmorphine | ✓ | | | |
| TRTAUA | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-Acetylmorphine | ✓ | | | |
| TUGNHJ | morphine | | 2015 | | ng/mL |
| | oxicodone | | 895 | | ng/mL |
| | 6-acetylmorphine | | 254 | | ng/mL |
| UR8YTF | Morphine | ✓ | | | |
| | 6-Monoacetylmorphine | ✓ | | | |
| UTH8CZ | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-acetylmorphine | ✓ | | | |
| | codeine | ✓ | | | |
| V2AXJT | morphine | | 2300 | 15% | ug/L |
| | oxycodone | | 780 | 15% | ug/L |
| | 6-acetylmorphine | | 190 | 15% | ug/L |
| VMBUCG | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| VV46MC | No drugs/metabolites detected utilizing confirmatory methods. | | | | |
| WWVHMA | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| X4AVWT | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-monoacetylmorpine | ✓ | | | |
| XCKWHT | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |

# TABLE 1B: Confirmatory Results - Item 1

| ***What drugs/metabolites were detected in Item 1?*** | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| XHU9GF | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-monoacetylmorphine (6MAM) | ✓ | | | |
| XTEFHP | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6 mono acetylmorphine | ✓ | | | |
| XZPYEU | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetyl-morphine | ✓ | | | |
| YCZT6D | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-acetylmorphine | ✓ | | | |
| YNDT4R | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetyl morphine | ✓ | | | |
| YQGNMV | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| Z4ZQF7 | No drugs/metabolites detected utilizing confirmatory methods. | | | | |
| ZBKTMA | morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |
| ZGR6XN | Morphine | ✓ | | | |
| | Oxycodone | ✓ | | | |
| | 6monoacetylmorphine | ✓ | | | |
| ZVQ26T | morphine | ✓ | | | |
| | oxycodone | ✓ | | | |
| | 6-monoacetylmorphine | ✓ | | | |

 

| Confirmatory Response Summary for Item 1 | Participants: 108 |
|---|---|
| Morphine: | 102 (94.4%) |
| Oxycodone: | 100 (92.6%) |
| 6-acetylmorphine: | 102 (94.4%) |
| Other Identified Drugs/Metabolites: | 1 (0.9%) |
| No Drugs/Metabolites Detected Utilizing Confirmatory Methods: | 3 (2.8%) |

# Raw Data - Item 1

TABLE 1C

**Item 1 Raw Data - Morphine**
**Preparation concentration: (2,400 ng/mL)**

| WebCode | List of Raw Data determinations (ng/mL) | |
|---|---|---|
| 98BFDM | 2,203.0 | |
| CT4N6Y | 2,404.7 | |
| RQLHHW | 2,214.0 | 2,174.0 |
| TUGNHJ | 2,015.0 | |
| V2AXJT | 2,249.0 | 2,350.0 |

## Statistical Analysis for Item 1 - Morphine

Please note: Statistical analysis has not been provided due to the low number of raw data responses.

# TABLE 1C: Raw Data - Item 1

**Item 1 Raw Data - Oxycodone**
**Preparation concentration: (800 ng/mL)**

| WebCode | List of Raw Data determinations (ng/mL) | |
|---|---|---|
| TUGNHJ | 895.0 | |
| V2AXJT | 771.0 | 789.0 |

## Statistical Analysis for Item 1 - Oxycodone

Please note: Statistical analysis has not been provided due to the low number of raw data responses.

# TABLE 1C: Raw Data - Item 1

**Item 1 Raw Data - 6-acetylmorphine**
**Preparation concentration: (200 ng/mL)**

| WebCode | List of Raw Data determinations (ng/mL) | |
|---|---|---|
| 76V339 | 283.3 | |
| 98BFDM | 160.0 | |
| BDRNV4 | 190.0 | |
| CT4N6Y | 179.0 | |
| RQLHHW | 182.0 | 185.0 |
| TUGNHJ | 254.0 | |
| V2AXJT | 185.0 | 190.0 |

## Statistical Analysis for Item 1 - 6-acetylmorphine

Please note: Statistical analysis has not been provided due to the low number of raw data responses.

# Reporting Procedures - Item 1

TABLE 1D - Item 1

| WebCode | Quantitative Reporting Procedures<br>*If quantitative analysis was performed, the reported concentrations are:* |
|---|---|
| 3RJMAY | A single determination. |
| 76V339 | A single determination. |
| 98BFDM | A single determination. |
| 9K27GY | Run in duplicate and compared to a reference material for qualitative identification. |
| BDRNV4 | A single determination. |
| CT4N6Y | A single determination. |
| GZP7MQ | A single determination. |
| RQLHHW | The mean of duplicate/several determinations. |
| TUGNHJ | A single determination. |
| V2AXJT | The mean of duplicate/several determinations. |

| Response Summary for Item 1 | | Participants: 10 |
|---|---|---|
| A single determination: | 7 (70.0%) | |
| The mean of duplicate/several determinations: | 2 (20.0%) | |
| Other: | 1 (10.0%) | |

# Methods of Analysis - Item 1

TABLE 1E - Item 1

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| 2JBUGR | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| 3743CY | LC/MS/MS | ✓ | ✓ | |
| 3AZRVQ | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | |
| | GC/MS | ✓ | ✓ | |
| 3RJMAY | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| 43TPZP | LC/MS/MS | ✓ | ✓ | ✓ |
| 4AFBFN | LC-HRMS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| 4AVRBG | Immunoassay | ✓ | | |
| | LC-QTOF | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | LC/MS/MS | | ✓ | |
| 4AYEMP | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| 4ET9KQ | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| 4YW39M | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| 6CGVE9 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| 6M2633 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| 6XECWG | Immunoassay | ✓ | | |
| 76V339 | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| 7AN9EP | Immunoassay | ✓ | | |
| 7E32DV | Immunoassay | ✓ | | |
| | LC-QTOF-MS | ✓ | | |
| | GC/MS | | ✓ | |
| 7TJU33 | Immunoassay | ✓ | | |
| | LC-QTOF | | ✓ | |
| | GC/MS | | ✓ | |
| 83PYUJ | High resolution accurate mass | ✓ | | |
| | GC/MS | | ✓ | |

# TABLE 1E: Methods of Analysis - Item 1

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| 8J9TG2 | Immunoassay | ✓ | | |
| | LC-QTOF | | ✓ | |
| 8WWUYT | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| 96RG6J | Immunoassay | ✓ | | |
| | LC/MS | | ✓ | |
| | GC/MS | | ✓ | |
| 98BFDM | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| 9K27GY | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| 9N397Z | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| 9PUCTF | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| A4APRT | LC/MS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| A7X4G3 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| A87HGG | Immunoassay | ✓ | | |
| AF6VNC | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| AFYTRC | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| | GC/MS | | ✓ | |
| ALQUEK | Immunoassay | ✓ | | |
| | LC/MS | ✓ | ✓ | |
| | GC/MS | | ✓ | |
| AMM82D | LC/MS/MS | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| AUKY62 | GC/MS | | ✓ | |
| B2Y873 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| BDRNV4 | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| BMJ8CX | Immunoassay | ✓ | | |
| | LC-QTOF | | ✓ | |
| BP6NUH | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | |
| | GC/MS | | ✓ | |

# TABLE 1E: Methods of Analysis - Item 1

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| BT9L24 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| C6TL8W | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC-QTOF | | ✓ | |
| CB3NBD | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| CDMTP3 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| CT4N6Y | Immunoassay | ✓ | | |
| | Orbitrap-LC/MS | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | LC/MS/MS | | ✓ | ✓ |
| D6DJZN | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| DJTMJX | LC/MS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| | Rapid Chromatographic Immunoassay | ✓ | | |
| EJPEUB | GC/MS | | ✓ | |
| | LC/HRMS | ✓ | ✓ | |
| EMPQQB | GC/MS | | ✓ | |
| | hrms | ✓ | | |
| EPD7WD | Immunoassay | ✓ | | |
| EWB2UB | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| F6LKQF | LC/MS/MS | | ✓ | |
| | GC/MS | ✓ | ✓ | |
| FF8JPX | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| FJ7VLX | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| FXK3FA | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | LC/MS/MS | | ✓ | |
| | GC/NPD | ✓ | | |
| G3QAED | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS | | ✓ | |
| GFG7GB | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | LC/MS/MS | ✓ | ✓ | |

# TABLE 1E: Methods of Analysis - Item 1

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| GRAEFD | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| GUKA4Q | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| GZLQ96 | Immunoassay | ✓ | | |
| GZP7MQ | LC/MS/MS | | | ✓ |
| HBLHEA | Immunoassay | ✓ | | |
| HPHQEX | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| HQF42P | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| JQ9FTB | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| KNE3R4 | LC/MS/MS | ✓ | ✓ | |
| KVY39G | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| L2447P | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | |
| LDU3QZ | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | |
| LDZAZM | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| LERDM3 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| LHPWN2 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| LQMJMT | LC/MS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| LX6WJ7 | GC/MS | ✓ | | |
| LYVVX6 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| M4Q32Y | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | |
| M6VYZ9 | LC/MS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| | Immunoassay | ✓ | | |

# TABLE 1E: Methods of Analysis - Item 1

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| M9UBV9 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LCQTOF | | ✓ | |
| MGR2KP | LC/MS/MS | ✓ | ✓ | |
| MNWK33 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| MU2CDL | Immunoassay | ✓ | | |
| | LC-QTOF | | ✓ | |
| | GC/MS | | ✓ | |
| MUJMT7 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| NK7TCH | LC/MS/MS | ✓ | ✓ | |
| NYNLZP | GC/MS | ✓ | ✓ | |
| P7KZZG | LC/MS/MS | ✓ | ✓ | |
| PG4AQV | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| PXQTHB | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| Q4EUZ2 | LC-HRMS/MS | ✓ | ✓ | |
| | GC/MS | | ✓ | |
| Q63FMW | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| | GC/MS | | ✓ | |
| QKXQGU | LC/MS/MS | | ✓ | |
| | Immunoassay | ✓ | | |
| | LC-QTOF-MS | ✓ | | |
| QQJTDY | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| QXKXCA | LC/MS/MS | ✓ | ✓ | |
| RDB8PZ | Immunoassay | ✓ | | |
| RQLHHW | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | GC-FID | | ✓ | ✓ |
| RYRJG2 | GC/MS | ✓ | ✓ | |
| TG94UK | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| TLRYZX | LC-HRMS/MS | ✓ | | |
| | GC/MS | | ✓ | |

 

# TABLE 1E: Methods of Analysis - Item 1

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| TMFE6Z | Immunoassay | ✓ | | |
| TNT2PY | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| TQFMCV | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| TRTAUA | GC/MS | ✓ | ✓ | |
| | Immunoassay | ✓ | | |
| TUGNHJ | LC/MS/MS | ✓ | | |
| | LC/MS | | ✓ | ✓ |
| | LC/HRMS | ✓ | | |
| UR8YTF | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| UTH8CZ | LC/MS/MS | ✓ | ✓ | |
| UY9DEG | Immunoassay | ✓ | | |
| V2AXJT | LC/MS | ✓ | | |
| | GC/MS | ✓ | | |
| | LC/MS/MS | | | ✓ |
| VMBUCG | GC/MS | | ✓ | |
| VV46MC | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| WWVHMA | LC/MS/MS | ✓ | ✓ | |
| X4AVWT | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| XCKWHT | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| XHU9GF | LC/MS | ✓ | ✓ | |
| XTEFHP | LC/MS/MS | ✓ | ✓ | |
| | Immunoassay | ✓ | | |
| XZPYEU | LC-HRMS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| YCZT6D | GC/MS | | ✓ | |
| YNDT4R | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | LC/MS/MS | | ✓ | |
| YQGNMV | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | ✓ | ✓ | |
| Z4ZQF7 | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |

# TABLE 1E: Methods of Analysis - Item 1

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| ZBKTMA | Immunoassay | ✓ | | |
| | LC-QTOF | | ✓ | |
| ZGR6XN | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| ZVQ26T | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | |
| | GC/MS | ✓ | ✓ | |

**Response Summary for Item 1 - Methods of Analysis** **Participants: 118**

| | Screening | Confirmatory | Quantitation |
|---|---|---|---|
| **Immunoassay:** | 86 | 0 | 0 |
| **GC/MS:** | 30 | 81 | 4 |
| **LC/MS:** | 3 | 5 | 1 |
| **LC/MS/MS:** | 22 | 39 | 6 |
| **Other:** | 14 | 10 | 1 |

 

# Additional Comments for Item 1

TABLE 1F

| WebCode | Item Comments |
|---|---|
| 3AZRVQ | Internal standards used include: mepivacaine and nalorphine |
| 43TPZP | Drugs included in panel: Cyclobenzaprine, Imipramine, MDPV, Meperidine, Mitragynine, Normeperidine, Phencyclidine, Quetiapine, and Zolpidem. |
| 4AFBFN | internal standards: mepivacaine, mephobarbital (Screen); internal standards: mepivacaine, nalorphine (confirmation) |
| 4AYEMP | internal standards: mepivacaine, nalorphine |
| 4ET9KQ | Mepivacaine was the internal standard used for all analysis. |
| 6XECWG | Opiate cutoff: 300ng/mL. Oxycodone cutoff: 100ng/mL. 6-acetylmorphine cutoff: 10 mg/mL. Creatinine: Normal |
| 76V339 | 6-Monoacetylmorphine results are above our upper limit of quantitation (200ng/mL). Oxycodone Cutoff 50 ng/mL. Morphine Cutoff 50 ng/mL |
| 7E32DV | Pseudephedrine and Heroin indicated- not confirmed. Caffine and Fluconazole- not reported |
| 83PYUJ | internal standard: mepivacaine |
| 8WWUYT | n-Propylamphetamine, Mepivacaine, and Hexobarbital used as internal standards. |
| 96RG6J | Mepivacaine and nalorphine used as internal standards |
| 98BFDM | Internal standard used for Opiates Analysis was Nalorphine |
| 9K27GY | Deuterated standards are used for compounds we can quantitate. Our lab is currently only able to quantitate samples that could contain basic drugs or cannabinoids. I have included the list of drugs the lab can quantitate or qualitatively identify: Amphetamine, Methamphetamine, MDA, MDMA, Ketamine, Mescaline (Qualitatively only), Phentermine, Diphenhydramine, LSD, Psilocin (qualitatively only), Ephedrine/Pseudoephedrine (qualitatively only), THC-OH, THC, THC-COOH. |
| 9PUCTF | Opiate Confirm: Internal Standard - Nalorphine |
| A7X4G3 | * Internal standard: flurazepam / estazolam. * Sample preparation: L/L extraction. * The final extraction is derivatized with BSTFA and injected by GC/MS. * LOD morphyne: 30 ng/mL. LOD 6-monoacetylmorphine: 15 ng/mL. LOD oxicodone: 30 ng/mL. |
| A87HGG | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL. |
| AF6VNC | Fluconazole indicated by GCMS. Not confirmed or reported. |
| BDRNV4 | Oxycodone Cutoff 50 ng/mL. Morphine Cutoff 50 ng/mL |
| CB3NBD | Nalorphine was used as an internal standard. |
| D6DJZN | Internal Standard: Mepivacaine, Nalorphine, Methohexital. Fluconazole - Not reported, no standard available for comparison |
| DJTMJX | Alere iCassette (THC) test device was used to screen for THC, referred to in 1-5 as rapid chromatographic immunoassay. The cutoff concentration for the assay is 50 ng/mL. |
| EMPQQB | Internal standards: Mepivacaine/Mephobarbital (HRMS) and Mepivacaine/Naloprhine (GCMS) |
| EPD7WD | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL. |

 

# TABLE 1F: Additional Comments for Item 1

| WebCode | Item Comments |
|---|---|
| G3QAED | mepivacaine and nalorphine were used as internal standards. |
| GFG7GB | Internal standards used were mepivacaine and nalorphine. |
| GRAEFD | Internal Standards: 1. SKF-525A 2. Hexobarbital |
| GUKA4Q | ELISA Benzodiazepines and zolpidem cut-offs set at 10ng/mL and 25ng/mL, respectively. ELISA Benzodiazepines and zolpidem screened at 126 and 105, respectively (slightly positive). LC/MS/MS confirmations for benzodiazepines and zolpidem were negative. |
| GZLQ96 | Opiate cutoff: 300ng/mL. Oxycodone cutoff: 100ng/mL. 6-acetylmorphine cutoff: 10 mg/mL. Creatinine: normal |
| HBLHEA | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL. |
| HQF42P | Confirmatory ISTD: NPA and SKF |
| KNE3R4 | Note: samples are not screened by an immunoassay screening method. All screening and confirmation conducted by LCMS |
| KVY39G | Sample was hydrolyzed so drugs represented are "total" not "free" |
| L2447P | Internal standard: Flurazepam and aprobarbital. LoD: 10 ng/mL. |
| LDU3QZ | Phenyltoloxamine, Buprenorphine-D4, Hydromorphone-D3, Oxycodone-D3 |
| LYVVX6 | Nalorphine used for opiate confirmation internal standard |
| M4Q32Y | LOQs: 6-MAM 1 ng/mL, morphine 10 ng/mL, oxycodone 10 ng/mL. Deuterated internal standards used for screening EMIT for immunoassay. |
| MNWK33 | Nalorphine used as Internal Standard for Opiate Extraction. |
| MU2CDL | IS used in QTOF analyses: Fentanyl-D5, Imipramine-D3, MDMA-D5, Methaqualone-D7, and Triazolam-D4. Caffeine, Ephedrine/Pseudoephedrine, and Fluconazole disregarded. |
| MUJMT7 | Internal standards utilized were mepivacaine and nalorphine. Morphine was butylated for analysis. |
| NK7TCH | Morphine-d6 ISTD LOD 5ng/ml; Oxycodone-d6 ISTD LOD 5ng/ml |
| P7KZZG | Morphine: ISTD: Morphine-d6; LOD: 5ng/mL. Oxycodone: ISTD: Oxycodone-d6; LOD: 5ng/mL |
| PG4AQV | At the time of this proficiency test, the laboratory temporarily suspended the reporting of quantitative results for opiates. Therefore, no quantitative results for opiates will be reported for this proficiency test. Only qualitative results will be reported. |
| PXQTHB | N-Propylamphetamine, Mepivacaine, and Hexobarbital were used as Internal Standards. |
| Q4EUZ2 | For LC-HRMS/MS testing, mepivacaine and mephobarbital were used as internal standards. For GC/MS testing, mepivacaine and nalorphine were used as internal standards. |
| Q63FMW | The cut off of morphine is 50 ng/mL. The cut off of oxycodone is 50 ng/mL. The cut off of 6-monacetylmorphine is 25 ng/mL. |
| QKXQGU | Confirmatory testing for acetaminophen not performed. |
| QXKXCA | ephedrine/pseudoephedrine detected in confirmation method- not reported as per provider- "verification testing showed low levels of ephedrine, fluconazole and pseudoephedrine in all three samples, please disregard these...." |
| RDB8PZ | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL. |

 

# TABLE 1F: Additional Comments for Item 1

| WebCode | Item Comments |
|---|---|
| RQLHHW | Morphine D3 internal standard. Calibration Curve for Morphine r2= 0.99. GC/FID for Alcohol confirmation - LLQ 20mg/dL - report less than 20mg/dL |
| TMFE6Z | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL. |
| TQFMCV | Codeine-D3 is used as an internal standard |
| TRTAUA | Screening GC/MS internal standards were Mepivacaine, Methohexital, and Nalorphine-diTMS. Confirmatory GC/MS internal standard was Mepivacaine. |
| UY9DEG | Analytes tested for and cutoffs provided below: Fentanyl 2 ng/ml, AB-Pinaca 2.5 ng/ml, Methamphetamine 200 ng/ml, Barbs 200 ng/ml, Benzos 150 ng/ml, Methadone 300 ng/ml, Opiates 200 ng/ml, Creatinine 20 mg/dl, Benzoylecgonine 150 ng/ml, Oxycodone 50 ng/ml, Tramadol 5 ng/ml, THC 20 ng/ml, TCA 150 ng/ml, Amphetamine 200 ng/ml, Buprenorphine 1 ng/ml, 6-mam 10 ng/ml, JWH-018 20 ng/ml, alpha-PVP 5 ng/ml, UR-144 10 ng/ml. |
| V2AXJT | oxycodone quantification ISD; d3-oxycodone morphine quantification ISD; d3-morphine 6-acetylmorphine quantification ISD; d3-acetylmorphine. |
| VV46MC | Item 1 screened presumptive positive for amphetamine using immunoassay. This is why confirmation was run, but no analytes were detected during the confirmation. The [Laboratory] does not currently have a validated method to confirm opiates or oxycodone/oxymorphone so no confirmatory testing was performed for these classes. |
| WWVHMA | Morphine-d6, LOD 5 ng/mL. Oxycodone-d6, LOD 5 ng/mL |
| X4AVWT | Opiate Confirmation : Internal Standard - Nalorphine |
| XCKWHT | Nalorphine used as internal standard for opiate confirmation |
| XHU9GF | Estazolam was used as internal standard. |
| XZPYEU | IS: mepivacaine, mephobarbital |
| YCZT6D | Internal standard: Flurazepam. |
| YNDT4R | mepivacaine was used as an retention time internal standard. Caffeine not reported. |
| YQGNMV | Mepivacaine and Nalorphine used as internal standards |
| ZGR6XN | Codeine-D3 is used as an internal standard |
| ZVQ26T | Internal standards: mepivacaine nalorphine |

 

# Screening Results - Item 2

TABLE 2A

Item Scenario:

A 30-year-old male was pulled over for swerving in between lanes. He was driving alone and seemed confused and drowsy. A urine sample was collected for analysis an hour after the incident had occurred.

Item Contents and Preparation Concentration: Fentanyl (150 ng/mL)
Norfentanyl (1,000 ng/mL)

| WebCode | Screening Results |
|---|---|
| 2JBUGR | No drugs detected utilizing screening methods. |
| 3743CY | Fentanyl<br>Norfentanyl |
| 3AZRVQ | Fentanyl |
| 3RJMAY | Fentanyl |
| 43TPZP | No drugs detected utilizing screening methods. |
| 4AFBFN | fentanyl |
| 4AVRBG | Fentanyl<br>norfentanyl |
| 4AYEMP | fentanyl |
| 4ET9KQ | No drugs detected utilizing screening methods. |
| 4YW39M | Fentanyl, Norfentanyl |
| 6CGVE9 | fentanyl<br>norfentanyl |
| 6M2633 | fentanyl, norfentanyl |
| 6XECWG | Fentanyl |
| 76V339 | Fentanyl |
| 7AN9EP | No drugs detected utilizing screening methods. |
| 7TJU33 | No drugs detected utilizing screening methods. |
| 83PYUJ | fentanyl |
| 8J9TG2 | No drugs detected utilizing screening methods. |
| 8WWUYT | Fentanyl (ELISA) |
| 96RG6J | No drugs detected utilizing screening methods. |
| 98BFDM | No drugs detected utilizing screening methods. |
| 9K27GY | Fentanyl<br>Amphetamine |

# TABLE 2A: Screening Results - Item 2

| WebCode | Screening Results |
|---|---|
| 9N397Z | fentanyl |
| 9PUCTF | Fentanyl, Norfentanyl |
| A4APRT | Methamphetamine, Norfentanyl, Fentanyl |
| A7X4G3 | No drugs detected utilizing screening methods. |
| A87HGG | Fentanyl |
| AF6VNC | Fentanyl |
| AFYTRC | Barbiturates<br>Cannabinoids<br>Fentanyl<br>Norfentanyl |
| ALQUEK | No drugs detected utilizing screening methods. |
| AMM82D | Fentanyl |
| AUKY62 | Fentanyl<br>Norfentanyl |
| B2Y873 | fentanyl, norfentanyl |
| BDRNV4 | Fentanyl<br>Gabapentin |
| BMJ8CX | No drugs detected utilizing screening methods. |
| BP6NUH | fentanyl |
| BT9L24 | No drugs detected utilizing screening methods. |
| C6TL8W | No drugs detected utilizing screening methods. |
| CB3NBD | Fentanyl<br>Norfentanyl |
| CDMTP3 | Fentanyl<br>Norfentanyl |
| CT4N6Y | Fentanyl<br>Norfentanyl |
| D6DJZN | No drugs detected utilizing screening methods. |
| DJTMJX | Norfentanyl, Fentanyl |
| EJPEUB | fentanyl |
| EMPQQB | fentanyl |

# TABLE 2A: Screening Results - Item 2

| WebCode | Screening Results |
|---|---|
| EPD7WD | Fentanyl |
| EWB2UB | No drugs detected utilizing screening methods. |
| F6LKQF | Opiates |
| FF8JPX | No drugs detected utilizing screening methods. |
| FJ7VLX | Fentanyl<br>Norfentanyl |
| FXK3FA | Fentanyl, Norfentanyl |
| G3QAED | No drugs detected utilizing screening methods. |
| GFG7GB | fentanyl |
| GRAEFD | 1. Fentanyl |
| GUKA4Q | Fentanyl<br>Benzodiazepines |
| GZLQ96 | Fentanyl |
| GZP7MQ | fentanyl<br>norfentanyl |
| HBLHEA | Fentanyl |
| HPHQEX | No drugs detected utilizing screening methods. |
| HQF42P | fentanyl |
| JQ9FTB | No drugs detected utilizing screening methods. |
| KNE3R4 | No drugs detected utilizing screening methods. |
| KVY39G | No drugs detected utilizing screening methods. |
| L2447P | OPIOIDS: Fentanyl and norfentanyl |
| LDU3QZ | Fentanyl<br>Norfentanyl |
| LDZAZM | Fentanyl |
| LERDM3 | Fentanyl<br>Norfentanyl |
| LHPWN2 | No drugs detected utilizing screening methods. |
| LQMJMT | fentanyl, norfentanyl |
| LX6WJ7 | Fentanyl |

 

# TABLE 2A: Screening Results - Item 2

| WebCode | Screening Results |
|---|---|
| LYVVX6 | Fentanyl, Norfentanyl |
| M4Q32Y | Fentanyl positive on immunoassay |
| M6VYZ9 | Fentanyl |
| M9UBV9 | Fentanyl |
| MGR2KP | Fentanyl, Norfentanyl |
| MNWK33 | Norfentanyl<br>Fentanyl |
| MU2CDL | No drugs detected utilizing screening methods. |
| MUJMT7 | No drugs detected utilizing screening methods. |
| NK7TCH | No drugs detected utilizing screening methods. |
| NYNLZP | Fentanyl |
| P7KZZG | No drugs detected utilizing screening methods. |
| PG4AQV | Fentanyl and norfentanyl |
| PXQTHB | ELISA Fentanyl |
| Q4EUZ2 | Fentanyl |
| Q63FMW | Fentanyl |
| QKXQGU | fentanyl, norfentanyl |
| QQJTDY | Fentanyl<br>Norfentanyl |
| QXKXCA | fentanyl, norfentanyl |
| RDB8PZ | Fentanyl |
| RQLHHW | No drugs detected utilizing screening methods. |
| RYRJG2 | fentanyl |
| TG94UK | No drugs detected utilizing screening methods. |
| TLRYZX | fentanyl |
| TMFE6Z | Fentanyl |
| TNT2PY | Fentanyl |
| TQFMCV | No drugs detected utilizing screening methods. |
| TRTAUA | Fentanyl, Norfentanyl |

 

# TABLE 2A: Screening Results - Item 2

| WebCode | Screening Results |
|---|---|
| TUGNHJ | fentanyl, norfentanyl |
| UR8YTF | No drugs detected utilizing screening methods. |
| UTH8CZ | fentanyl |
| UY9DEG | Fentanyl |
| V2AXJT | fentanyl<br>norfentanyl |
| VMBUCG | No drugs detected utilizing screening methods. |
| VV46MC | Fentanyl, Amphetamine |
| WWVHMA | No drugs detected utilizing screening methods. |
| X4AVWT | Fentanyl<br>Norfentanyl |
| XCKWHT | Fentanyl and Norfentanyl |
| XHU9GF | Fentanyl<br>Norfentanyl |
| XTEFHP | Fentanyl<br>Norfentanyl |
| XZPYEU | fentanyl |
| YCZT6D | No drugs detected utilizing screening methods. |
| YNDT4R | fentanyl |
| YQGNMV | fentanyl |
| Z4ZQF7 | Fentanyl |
| ZBKTMA | No drugs detected utilizing screening methods. |
| ZGR6XN | No drugs detected utilizing screening methods. |
| ZVQ26T | fentanyl |

| Screening Response Summary for Item 2 | Participants: 117 |
|---|---|
| Fentanyl: | 81 |
| Norfentanyl: | 35 |
| Other drugs/metabolites detected: | 8 |
| No drugs/metabolites detected Utilizing Screening Methods: | 35 |

Total number of screening responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

# Confirmatory Results - Item 2

TABLE 2B

Item Scenario:

A 30-year-old male was pulled over for swerving in between lanes. He was driving alone and seemed confused and drowsy. A urine sample was collected for analysis an hour after the incident had occurred.

Item Contents and Preparation Concentration: Fentanyl (150 ng/mL)
Norfentanyl (1,000 ng/mL)

***What drugs/metabolites were detected in Item 2?***

| WebCode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---|---|---|---|---|---|
| 2JBUGR | fentanyl | ✓ | | | |
| 3743CY | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| 3AZRVQ | Fentanyl | ✓ | | | |
| 3RJMAY | fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| 43TPZP | No drugs/metabolites detected utilizing confirmatory methods. | | | | |
| 4AFBFN | fentanyl | ✓ | | | |
| 4AVRBG | fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| 4AYEMP | fentanyl | ✓ | | | |
| 4ET9KQ | fentanyl | ✓ | | | |
| 4YW39M | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| 6CGVE9 | fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| 6M2633 | fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| 76V339 | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| 7AN9EP | No drugs/metabolites detected utilizing confirmatory methods. | | | | |
| 7TJU33 | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| 83PYUJ | fentanyl | ✓ | | | |
| 8J9TG2 | fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |

# TABLE 2B: Confirmatory Results - Item 2

| ***What drugs/metabolites were detected in Item 2?*** | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| 8WWUYT | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| 96RG6J | fentanyl | ✓ | | | |
| 98BFDM | Fentanyl | ✓ | | | |
| 9K27GY | Ephedrine/Pseudoephedrine | ✓ | | | |
| 9N397Z | fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| 9PUCTF | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| A4APRT | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| A7X4G3 | Fentanyl | ✓ | | | |
| AF6VNC | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| AFYTRC | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| ALQUEK | fentanyl | ✓ | | | |
| AMM82D | Fentanyl | ✓ | | | |
| AUKY62 | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| B2Y873 | fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| BDRNV4 | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| BMJ8CX | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| BP6NUH | fentanyl | ✓ | | | |
| BT9L24 | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| C6TL8W | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |

# TABLE 2B: Confirmatory Results - Item 2

| *What drugs/metabolites were detected in Item 2?* | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| CB3NBD | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| CDMTP3 | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| CT4N6Y | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| D6DJZN | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| DJTMJX | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| EJPEUB | fentanyl | ✓ | | | |
| EMPQQB | fentanyl | ✓ | | | |
| EWB2UB | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| F6LKQF | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| FF8JPX | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| FJ7VLX | Fentanyl | ✓ | | | |
| | Nrfentanyl | ✓ | | | |
| FXK3FA | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| G3QAED | fentanyl | ✓ | | | |
| GFG7GB | fentanyl | ✓ | | | |
| GRAEFD | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| GUKA4Q | No drugs/metabolites detected utilizing confirmatory methods. | | | | |
| GZP7MQ | fentanyl | | 0,12 | | mg/l |
| | Norfentanyl | | 0,40 | | mg/l |
| HPHQEX | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |

# TABLE 2B: Confirmatory Results - Item 2

| ***What drugs/metabolites were detected in Item 2?*** | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| HQF42P | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| | acetyl fentanyl | ✓ | | | |
| JQ9FTB | Fentanyl | ✓ | | | |
| KNE3R4 | fentanyl | ✓ | | | |
| KVY39G | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| L2447P | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| LDU3QZ | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| LDZAZM | Fentanyl | ✓ | | | |
| LERDM3 | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| LHPWN2 | fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| LQMJMT | fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| LYVVX6 | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| M4Q32Y | No drugs/metabolites detected utilizing confirmatory methods. | | | | |
| M6VYZ9 | Fentanyl | ✓ | | | |
| M9UBV9 | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| MGR2KP | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| MNWK33 | Fentanyl | | | | |
| | Norfentanyl | ✓ | | | |
| MU2CDL | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| MUJMT7 | Fentanyl | ✓ | | | |

# TABLE 2B: Confirmatory Results - Item 2

| ***What drugs/metabolites were detected in Item 2?*** | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| NYNLZP | Fentanyl | ✓ | | | |
| PG4AQV | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| PXQTHB | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| Q4EUZ2 | Fentanyl | ✓ | | | |
| Q63FMW | Fentanyl | ✓ | | | |
| QKXQGU | fentanyl | ✓ | | | |
| QQJTDY | Fentanyl | | | | |
| | Norfentanyl | | | | |
| QXKXCA | fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| RYRJG2 | No drugs/metabolites detected utilizing confirmatory methods. | | | | |
| TG94UK | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| TLRYZX | fentanyl | ✓ | | | |
| TNT2PY | Fentanyl | ✓ | | | |
| TQFMCV | Fentanyl | ✓ | | | |
| TRTAUA | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| TUGNHJ | fentanyl | | 86.4 | 13,6% | ng/mL |
| | Norfentanyl | | >500 | | ng/mL |
| UTH8CZ | fentanyl | ✓ | | | |
| V2AXJT | fentanyl | | | | |
| | Norfentanyl | | | | |
| VMBUCG | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| W46MC | No drugs/metabolites detected utilizing confirmatory methods. | | | | |
| X4AVWT | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |

# TABLE 2B: Confirmatory Results - Item 2

| ***What drugs/metabolites were detected in Item 2?*** | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| XCKWHT | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| XHU9GF | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| XTEFHP | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| XZPYEU | fentanyl | ✓ | | | |
| YCZT6D | Fentanyl | ✓ | | | |
| YNDT4R | fentanyl | ✓ | | | |
| YQGNMV | fentanyl | ✓ | | | |
| Z4ZQF7 | No drugs/metabolites detected utilizing confirmatory methods. | | | | |
| ZBKTMA | Fentanyl | ✓ | | | |
| | Norfentanyl | ✓ | | | |
| ZGR6XN | Fentanyl | ✓ | | | |
| ZVQ26T | fentanyl | ✓ | | | |

| **Confirmatory Response Summary for Item 2** | **Participants: 103** |
|---|---|
| Fentanyl: | 95 (92.2%) |
| Norfentanyl: | 60 (58.3%) |
| Other Identified Drugs/Metabolites: | 1 (1.0%) |
| No Drugs/Metabolites Detected Utilizing Confirmatory Methods: | 7 (6.8%) |

# Raw Data - Item 2

TABLE 2C

**Item 2 Raw Data - Fentanyl**
**Preparation concentration: (150 ng/mL)**

| WebCode | List of Raw Data determinations (ng/mL) |
|---|---|
| TUGNHJ | 86.40 |

## Statistical Analysis for Item 2 - Fentanyl

Please note: Statistical analysis has not been provided due to the low number of raw data responses.

# TABLE 2C: Raw Data - Item 2

**Item 2 Raw Data - Norfentanyl**
**Preparation concentration: (1,000 ng/mL)**

| WebCode | List of Raw Data determinations (ng/mL) |
|---|---|
| TUGNHJ | 626.0 |

## Statistical Analysis for Item 2 - Norfentanyl

Please note: Statistical analysis has not been provided due to the low number of raw data responses.

# Reporting Procedures - Item 2

TABLE 2D - Item 2

| Quantitative Reporting Procedures | |
|---|---|
| **WebCode** | ***If quantitative analysis was performed, the reported concentrations are:*** |
| 9K27GY | Run in duplicate and compared to a reference material for qualitative identification. |
| TUGNHJ | A single determination. |

| Response Summary for Item 2 | Participants: 2 |
|---|---|
| A single determination: | 1 (50.0%) |
| The mean of duplicate/several determinations: | 0 (0.0%) |
| Other: | 1 (50.0%) |

# Methods of Analysis - Item 2

TABLE 2E - Item 2

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| 2JBUGR | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | ✓ | ✓ | |
| 3743CY | LC/MS/MS | ✓ | ✓ | |
| 3AZRVQ | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | |
| | GC/MS | ✓ | ✓ | |
| 3RJMAY | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| 43TPZP | LC/MS/MS | ✓ | ✓ | ✓ |
| 4AFBFN | LC-HRMS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| 4AVRBG | Immunoassay | ✓ | | |
| | LC-QOTF | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | LC/MS/MS | | ✓ | |
| 4AYEMP | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| 4ET9KQ | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| 4YW39M | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| 6CGVE9 | GC/MS | ✓ | ✓ | |
| 6M2633 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| 6XECWG | Immunoassay | ✓ | | |
| 76V339 | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| 7AN9EP | Immunoassay | ✓ | | |
| 7TJU33 | Immunoassay | ✓ | | |
| | LC-QTOF | | ✓ | |
| | GC/MS | | ✓ | |
| 83PYUJ | High resolution accurate mass | ✓ | | |
| | GC/MS | | ✓ | |
| 8J9TG2 | Immunoassay | ✓ | | |
| | LC-QTOF | | ✓ | |
| | GC/MS | | ✓ | |

# TABLE 2E: Methods of Analysis - Item 2

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| 8WWUYT | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| 96RG6J | Immunoassay | ✓ | | |
| | LC/MS | | ✓ | |
| | GC/MS | | ✓ | |
| 98BFDM | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| 9K27GY | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| 9N397Z | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| 9PUCTF | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| A4APRT | LC/MS/MS | ✓ | ✓ | |
| | GC/MS | | ✓ | |
| A7X4G3 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| A87HGG | Immunoassay | ✓ | | |
| AF6VNC | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| AFYTRC | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | LC/MS/MS | | ✓ | |
| ALQUEK | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | LC/MS | ✓ | ✓ | |
| AMM82D | LC/MS/MS | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| AUKY62 | GC/MS | | ✓ | |
| B2Y873 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| BDRNV4 | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| BMJ8CX | GC/MS | | ✓ | |
| | LC-QTOF | | ✓ | |
| BP6NUH | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | |
| | GC/MS | | ✓ | |
| BT9L24 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |

# TABLE 2E: Methods of Analysis - Item 2

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| C6TL8W | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC-QTOF | | ✓ | |
| CB3NBD | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| CDMTP3 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| CT4N6Y | Orbitrap-LC/MS | ✓ | | |
| | LC/MS | | ✓ | |
| D6DJZN | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| DJTMJX | LC/MS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| | Rapid Chromatographic Immunoassay | ✓ | | |
| EJPEUB | GC/MS | | ✓ | |
| | LC/HRMS | ✓ | ✓ | |
| EMPQQB | HRMS | ✓ | | |
| | GC/MS | | ✓ | |
| EPD7WD | Immunoassay | ✓ | | |
| EWB2UB | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| F6LKQF | LC/MS/MS | | ✓ | |
| | GC/MS | ✓ | ✓ | |
| FF8JPX | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| FJ7VLX | GC/MS | ✓ | ✓ | |
| FXK3FA | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | |
| | GC/NPD | ✓ | | |
| G3QAED | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS | | ✓ | |
| GFG7GB | LC/MS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| | Immunoassay | ✓ | | |
| GRAEFD | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| GUKA4Q | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |

# TABLE 2E: Methods of Analysis - Item 2

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| GZLQ96 | Immunoassay | ✓ | | |
| GZP7MQ | LC/MS/MS | | | |
| HBLHEA | Immunoassay | ✓ | | |
| HPHQEX | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| HQF42P | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS | | ✓ | |
| JQ9FTB | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| KNE3R4 | LC/MS/MS | ✓ | ✓ | |
| KVY39G | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| L2447P | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | |
| LDU3QZ | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | |
| LDZAZM | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| LERDM3 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| LHPWN2 | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| LQMJMT | LC/MS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| LX6WJ7 | GC/MS | ✓ | | |
| LYVVX6 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| M4Q32Y | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | |
| M6VYZ9 | LC/MS/MS | ✓ | | |
| | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| M9UBV9 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LCQTOF | | ✓ | |
| MGR2KP | LC/MS/MS | ✓ | ✓ | |
| MNWK33 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |

 

# TABLE 2E: Methods of Analysis - Item 2

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| MU2CDL | Immunoassay | ✓ | | |
| | LC-QTOF | | ✓ | |
| | GC/MS | | ✓ | |
| MUJMT7 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| NK7TCH | LC/MS/MS | ✓ | | |
| NYNLZP | GC/MS | ✓ | ✓ | |
| P7KZZG | LC/MS/MS | ✓ | | |
| PG4AQV | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| PXQTHB | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| Q4EUZ2 | LC-HRMS/MS | ✓ | ✓ | |
| | GC/MS | | ✓ | |
| Q63FMW | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| QKXQGU | LC-QTOF-MS | ✓ | | |
| | LC/MS/MS | | ✓ | |
| | Immunoassay | ✓ | | |
| QQJTDY | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | |
| QXKXCA | LC/MS/MS | ✓ | ✓ | |
| RDB8PZ | Immunoassay | ✓ | | |
| RQLHHW | Immunoassay | ✓ | | |
| | GC/FID | | ✓ | ✓ |
| RYRJG2 | GC/MS | ✓ | ✓ | |
| TG94UK | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| TLRYZX | LC-HRMS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| TMFE6Z | Immunoassay | ✓ | | |
| TNT2PY | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| TQFMCV | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| TRTAUA | GC/MS | ✓ | ✓ | |
| | Immunoassay | ✓ | | |

 

# TABLE 2E: Methods of Analysis - Item 2

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| TUGNHJ | LC/MS/MS | ✓ | ✓ | ✓ |
| | LC/HRMS | ✓ | | |
| UR8YTF | Immunoassay | ✓ | | |
| UTH8CZ | LC/MS/MS | ✓ | ✓ | |
| UY9DEG | Immunoassay | ✓ | | |
| V2AXJT | GC/MS | ✓ | | |
| | LC/MS | ✓ | | |
| VMBUCG | GC/MS | | ✓ | |
| VV46MC | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| WWVHMA | LC/MS/MS | ✓ | | |
| X4AVWT | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| XCKWHT | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| XHU9GF | LC/MS | ✓ | ✓ | |
| XTEFHP | LC/MS/MS | ✓ | ✓ | |
| | Immunoassay | ✓ | | |
| XZPYEU | LC-HRMS/MS | ✓ | ✓ | |
| YCZT6D | GC/MS | | ✓ | |
| YNDT4R | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | LC/MS/MS | | ✓ | |
| YQGNMV | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | |
| | GC/MS | | ✓ | |
| Z4ZQF7 | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| ZBKTMA | Immunoassay | ✓ | | |
| | LC-QTOF | | ✓ | |
| | GC/MS | | ✓ | |
| ZGR6XN | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| ZVQ26T | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | |
| | GC/MS | ✓ | ✓ | |

| Response Summary for Item 2 - Methods of Analysis | | | Participants: 117 |
|---|---|---|---|
| | **Screening** | **Confirmatory** | **Quantitation** |
| **Immunoassay:** | 81 | 0 | 0 |
| **GC/MS:** | 37 | 73 | 0 |
| **LC/MS:** | 3 | 6 | 0 |
| **LC/MS/MS:** | 23 | 41 | 2 |
| **Other:** | 13 | 11 | 1 |

# Additional Comments for Item 2

TABLE 2F

| WebCode | Item Comments |
|---|---|
| 3743CY | There was an indication of acetylfentanyl and acetylnorfentanyl but they were both below our limits of confirmation (0.5ng/mL). |
| 3AZRVQ | Internal standards used: Mepivacaine |
| 43TPZP | Drugs included in panel: Cyclobenzaprine, Imipramine, MDPV, Meperidine, Mitragynine, Normeperidine, Phencyclidine, Quetiapine, and Zolpidem. |
| 4AFBFN | internal standards: mepivacaine, mephobarbital (Screen). internal standards: mepivacaine (confirmation) |
| 4AYEMP | internal standard: mepivacaine |
| 4ET9KQ | Mepivacaine was the internal standard used for all analysis. |
| 6XECWG | Fentanyl cutoff: 1.0 ng/mL, Creatinine: Normal |
| 76V339 | Fentanyl Cutoff 5 ng/mL. Norfentanyl Cutoff 5 ng/mL |
| 83PYUJ | Internal standard: mepivacaine |
| 8WWUYT | n-Propylamphetamine, Mepivacaine, and Hexobarbital used as internal standards. |
| 96RG6J | Mepivacaine used as internal standard |
| 9K27GY | Deuterated standards are used for compounds we can quantitate. Our lab is currently only able to quantitate samples that could contain basic drugs or cannabinoids. I have included the list of drugs the lab can quantitate or qualitatively identify: Amphetamine, Methamphetamine, MDA, MDMA, Ketamine, Mescaline (Qualitatively only), Phentermine, Diphenhydramine, LSD, Psilocin (qualitatively only), Ephedrine/Pseudoephedrine (qualitatively only), THC-OH, THC, THC-COOH, THC-COOH. |
| A4APRT | Methamphetamine was not detected by the confirmatory analysis. |
| A7X4G3 | * Internal standard: flurazepam / estazolam. * Sample preparation: L/L extraction. * The final extraction is derivatized with BSTFA and injected by GC-MS. * LOD fentanyl: 15 ng/mL. |
| A87HGG | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL |
| AF6VNC | Fluconazole indicated by GCMS. Not confirmed or reported. |
| BDRNV4 | Fentanyl Cutoff 5 ng/mL. Norfentanyl Cutoff 5 ng/mL |
| D6DJZN | Internal Standard: Mepivacaine, Nalorphine, Methohexital Fluconazole - Not reported, no standard available for comparison |
| DJTMJX | Alere iCassette (THC) test device was used to screen for THC, referred to in 2-5 as rapid chromatographic immunoassay. The cutoff concentration for the assay is 50 ng/mL. |
| EMPQQB | Internal standards: Mepivacaine/Mephobarbital (HRMS) and Mepivacaine/Naloprhine (GCMS) |
| EPD7WD | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL |
| G3QAED | mepivacaine was used as an internal standard. |
| GFG7GB | Internal standard used was mepivacaine. |
| GRAEFD | Internal Standards 1. SKF-525A 2. Hexobarbital |

 

# TABLE 2F: Additional Comments for Item 2

| WebCode | Item Comments |
|---|---|
| GUKA4Q | No in-house confirmation test method for fentanyl in urine, this sample would have been sent to an outside laboratory for confirmation. ELISA Benzodiazepines cut-off set at 10ng/mL. ELISA Benzodiazepines screened at 115 (slightly positive). LC/MS/MS confirmation for benzodiazepines was negative. |
| GZLQ96 | Fentanyl cutoff: 1.0 ng/mL, Creatinine: normal |
| HBLHEA | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL. |
| HQF42P | Confirmatory GC/MS ISTD: NPA and SKF. Confirmatory LC/MS ISTD: Fentanyl-13C6 and Beta-hydroxythio-fentanyl-13C6 |
| KNE3R4 | Note: samples are not screened by an immunoassay screening method. All screening and confirmation conducted by LCMS |
| L2447P | The metabolite norfentanyl was identified by GC-MS and LC-MS-MS library match, as to the lab does not have reference material available. Internal standard: Flurazepam and aprobarbital. LoD: 10 ng/mL. |
| LDU3QZ | Phenyltoloxamine, Buprenorphine-D4, Hydromorphone-D3, Oxycodone-D3 |
| M4Q32Y | Fentanyl immunoassay (EMIT) positive. Fentanyl and norfentanyl were below our LOD/LOQ for confirmation testing. LOQ for fentanyl was 1 ng/mL, norfentanyl is 10 ng/mL. Deuterated internal standards used. |
| MU2CDL | IS used in QTOF analyses: Fentanyl-D5, Imipramine-D3, MDMA-D5, Methaqualone-D7, and Triazolam-D4. Caffeine, Ephedrine/Pseudoephedrine, and Fluconazole disregarded. |
| MUJMT7 | Internal standard utilized was mepivacaine. |
| PG4AQV | The immunoassay screening results were negative for drugs. The immunoassay method only screens for the following drugs/drug classes: Amphetamines, Benzodiazepines, Cannabinoids, Cocaine, Opiates, and PCP. Fentanyl does not react with the Opiates panel and is not part of the immunoassay screening panel. A GC/MS scan was performed as a secondary screen and fentanyl and norfentanyl were detected. Fentanyl and norfentanyl were then confirmed on the GC/MS. |
| PXQTHB | N-Propylamphetamine, Mepivacaine, and Hexobarbital were used as Internal Standards. |
| Q4EUZ2 | For LC-HRMS/MS testing, mepivacaine and mephobarbital were used as internal standards. For GC/MS testing, mepivacaine and nalorphine were used as internal standards |
| Q63FMW | The cut off of fentanyl is 5 ng/mL |
| QXKXCA | ephedrine/pseudoephedrine detected in confirmation method- not reported as per provider- "verification testing showed low levels of ephedrine, fluconazole and pseudoephedrine in all three samples, please disregard these...." |
| RDB8PZ | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL |
| RQLHHW | GC/FID for Alcohol confirmation - LLQ 20mg/dL - report less than 20mg/dL |
| TMFE6Z | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL. |
| TQFMCV | Codeine-D3 is used as an internal standard |
| TRTAUA | Screening GC/MS internal standards were Mepivacaine, Methohexital, and Nalorphine-diTMS. Confirmatory GC/MS internal standard was Mepivacaine. |

 

# TABLE 2F: Additional Comments for Item 2

| WebCode | Item Comments |
|---|---|
| UY9DEG | Analytes tested for and cutoffs provided below: Fentanyl 2 ng/ml, AB-Pinaca 2.5 ng/ml, Methamphetamine 200 ng/ml, Barbs 200 ng/ml, Benzos 150 ng/ml, Methadone 300 ng/ml, Opiates 200 ng/ml, Creatinine 20 mg/dl, Benzoylecgonine 150 ng/ml, Oxycodone 50 ng/ml, Tramadol 5 ng/ml, THC 20 ng/ml, TCA 150 ng/ml, Amphetamine 200 ng/ml, Buprenorphine 1 ng/ml, 6-mam 10 ng/ml, JWH-018 20 ng/ml, alpha-PVP 5 ng/ml, UR-144 10 ng/ml. |
| V2AXJT | Confirmation by two screening techniques |
| VV46MC | Item 1 screened presumptive positive for amphetamine using immunoassay. This is why confirmation was run, but no analytes were detected during the confirmation. The [Laboratory] does not currently have a validated method to confirm fentanyl so no confirmatory testing was performed for this class. |
| XHU9GF | Estazolam was used as internal standard. |
| XZPYEU | IS: mepivacaine, mephobarbital |
| YCZT6D | Internal standard: Flurazepam. |
| YNDT4R | Mepivacaine was used as an retention time internal standard. Caffeine not reported. |
| YQGNMV | Mepivacaine used as internal standard |
| ZGR6XN | Codeine-D3 is used as an internal standard |
| ZVQ26T | Internal standard: mepivacaine |

 

# Screening Results - Item 3

TABLE 3A

Item Scenario:

A 17-year-old female high school student receiving an annual physical complained of being tired. She reported extreme mood swings and insomnia. A urine sample was collected for analysis.

Item Contents and Preparation Concentration: Amphetamine (600ng/mL)

| WebCode | Screening Results |
|---|---|
| 2JBUGR | No drugs detected utilizing screening methods. |
| 3743CY | Amphetamine |
| 3AZRVQ | amphetamines --> l-amphetamine and d-amphetamine |
| 3RJMAY | No drugs detected utilizing screening methods. |
| 43TPZP | No drugs detected utilizing screening methods. |
| 4AFBFN | amphetamine |
| 4AVRBG | amphetamine |
| 4AYEMP | amphetamine |
| 4ET9KQ | No drugs detected utilizing screening methods. |
| 4YW39M | SMA |
| 6CGVE9 | amphetamine |
| 6M2633 | SMAs |
| 6XECWG | [Participant reported that drugs were detected, but did not report the drug class or name] |
| 76V339 | No drugs detected utilizing screening methods. |
| 7AN9EP | Amphetamines |
| 7TJU33 | Amphetamine |
| 83PYUJ | amphetamine |
| 8J9TG2 | amphetamines |
| 8WWUYT | Amphetamine (GC/MS) |
| 96RG6J | No drugs detected utilizing screening methods. |
| 98BFDM | Amphetamine |
| 9K27GY | Benzoylecgonine/Cocaine<br>Methamphetamine<br>Amphetamine |
| 9N397Z | No drugs detected utilizing screening methods. |
| 9PUCTF | Amphetamine (class); Possible SMA (Sympathomimetic amine) |

 

# TABLE 3A: Screening Results - Item 3

| WebCode | Screening Results |
|---|---|
| A4APRT | Amphetamine |
| A7X4G3 | UNCERTAIN AMPHETAMINES |
| A87HGG | No drugs detected utilizing screening methods. |
| AF6VNC | Amphetamines |
| AFYTRC | Cannabinoids<br>Amphetamine |
| ALQUEK | No drugs detected utilizing screening methods. |
| AMM82D | Amphetamine |
| AUKY62 | Amphetamine |
| B2Y873 | amphetamines |
| BDRNV4 | No drugs detected utilizing screening methods. |
| BMJ8CX | Amphetamines |
| BP6NUH | amphetamine |
| BT9L24 | Amphetamines |
| C6TL8W | Amphetamine |
| CB3NBD | SMA |
| CDMTP3 | Amphetamine |
| CT4N6Y | Amphetamine |
| DJTMJX | Amphetamine |
| EJPEUB | l-amphetamine & d-amphetamine |
| EMPQQB | amphetamine |
| EPD7WD | No drugs detected utilizing screening methods. |
| EWB2UB | Amphetamine. |
| F6LKQF | Amphetamine |
| FF8JPX | Amphetamine |
| FJ7VLX | Amphetamine |
| FXK3FA | Amphetamine |
| G3QAED | No drugs detected utilizing screening methods. |
| GFG7GB | amphetamine |

 

# TABLE 3A: Screening Results - Item 3

| WebCode | Screening Results |
|---|---|
| GRAEFD | 1. Amphetamine |
| GUKA4Q | Amphetamines<br>Benzodiazepines |
| GZLQ96 | [Participant reported that drugs were detected, but did not report the drug class or name] |
| GZP7MQ | ampetamine |
| HBLHEA | No drugs detected utilizing screening methods. |
| HPHQEX | Amphetamine EMIT positive |
| HQF42P | amphetamine |
| JQ9FTB | Amphetamine < cuttoff |
| KNE3R4 | No drugs detected utilizing screening methods. |
| KVY39G | No drugs detected utilizing screening methods. |
| L2447P | Stimulants: Amphetamine |
| LDU3QZ | Amphetamine |
| LDZAZM | Amphetamine |
| LERDM3 | SMA's |
| LHPWN2 | No drugs detected utilizing screening methods. |
| LQMJMT | amphetamine |
| LX6WJ7 | No drugs detected utilizing screening methods. |
| LYVVX6 | Sympathomimetic Amines (SMA) |
| M4Q32Y | Immunoassay negative (amphetamine class deflected)<br>Amphetamine confirmation present |
| M6VYZ9 | Amphetamine |
| M9UBV9 | Amphetamine |
| MGR2KP | Amphetamine |
| MNWK33 | SMA- Amphetamine |
| MU2CDL | Amphetamine |
| MUJMT7 | No drugs detected utilizing screening methods. |
| NK7TCH | Amphetamine |
| NYNLZP | No drugs detected utilizing screening methods. |

 

# TABLE 3A: Screening Results - Item 3

| WebCode | Screening Results |
|---|---|
| P7KZZG | Amphetamine |
| PG4AQV | No drugs detected utilizing screening methods. |
| PXQTHB | Amphetamine (GC/MS) |
| Q4EUZ2 | l-amphetamine, d-amphetamine |
| Q63FMW | Amphetamine |
| QKXQGU | BMPEA/amphetamine |
| QQJTDY | Amphetamine |
| QXKXCA | amphetamine |
| RDB8PZ | No drugs detected utilizing screening methods. |
| RQLHHW | No drugs detected utilizing screening methods. |
| RYRJG2 | amphetamine |
| TG94UK | Sympathomimetic amines |
| TLRYZX | l-amphetamine<br>d-amphetamine |
| TMFE6Z | No drugs detected utilizing screening methods. |
| TNT2PY | Amphetamines |
| TQFMCV | No drugs detected utilizing screening methods. |
| TRTAUA | Amphetamine/MDA, Amphetamine |
| TUGNHJ | amphetamine |
| UR8YTF | Amphetamine |
| UTH8CZ | amphetamine |
| UY9DEG | Amphetamine |
| V2AXJT | amphetamine |
| VMBUCG | No drugs detected utilizing screening methods. |
| VV46MC | Methamphetamine, amphetamine |
| WWVHMA | Amphetamine |
| X4AVWT | Amphetamine Class |
| XCKWHT | Amphetamines (SMAs) |
| XHU9GF | Amphetamine |

 

# TABLE 3A: Screening Results - Item 3

| WebCode | Screening Results |
|---|---|
| XTEFHP | Amphetamine |
| XZPYEU | d-amphetamine, l-amphetamine |
| YCZT6D | No drugs detected utilizing screening methods. |
| YNDT4R | amphetamine |
| YQGNMV | d-amphetamine, l-amphetamine |
| Z4ZQF7 | Amphetamine |
| ZBKTMA | Amphetamine |
| ZGR6XN | No drugs detected utilizing screening methods. |
| ZVQ26T | amphetamine |

| Screening Response Summary for Item 3 | Participants: 116 |
|---|---|
| Amphetamine: | 87 |
| Other drugs/metabolites detected: | 14 |
| No drugs/metabolites detected Utilizing Screening Methods: | 27 |

Total number of screening responses provided may be more than the number of participants due to multiple drugs/metabolites being reported.

 

# Confirmatory Results - Item 3

TABLE 3B

Item Scenario:

A 17-year-old female high school student receiving an annual physical complained of being tired. She reported extreme mood swings and insomnia. A urine sample was collected for analysis.

Item Contents and Preparation Concentration: Amphetamine (600ng/mL)

***What drugs/metabolites were detected in Item 3?***

| WebCode | Analyte Reported | Qualitative Only | Reported Concentration | Uncertainty | Units |
|---|---|---|---|---|---|
| 2JBUGR | d-amphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |
| 3743CY | Amphetamine | ✓ | | | |
| 3AZRVQ | d-amphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |
| 3RJMAY | amphetamine | ✓ | | | |
| 43TPZP | No drugs/metabolites detected utilizing confirmatory methods. | | | | |
| 4AFBFN | d-amphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |
| 4AVRBG | amphetamine | ✓ | | | |
| 4AYEMP | d-amphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |
| 4ET9KQ | d-amphetamine | ✓ | | | |
| | l-amphetamine | | | | |
| 4YW39M | Amphetamine | ✓ | | | |
| 6CGVE9 | amphetamine | ✓ | | | |
| 6M2633 | amphetamine | ✓ | | | |
| 7AN9EP | Amphetamine | | 579.56 | 2.32 | ng/ml |
| 7TJU33 | Amphetamine | ✓ | | | |
| 83PYUJ | d-amphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |
| 8J9TG2 | Amphetamine | ✓ | | | |
| 8WWUYT | Amphetamine | ✓ | | | |
| 96RG6J | d-amphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |
| 98BFDM | No drugs/metabolites detected utilizing confirmatory methods. | | | | |

# TABLE 3B: Confirmatory Results - Item 3

| ***What drugs/metabolites were detected in Item 3?*** | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| 9K27GY | Amphetamine | | 456 | 160 | ng/mL |
| | Ephedrine/Pseudoephedrine | ✓ | | | |
| 9PUCTF | Amphetamine | ✓ | | | |
| A4APRT | Amphetamine | ✓ | | | |
| A7X4G3 | Amphetamine | ✓ | | | |
| AF6VNC | Amphetamine | ✓ | | | |
| AFYTRC | Amphetamine | ✓ | | | |
| ALQUEK | d-amphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |
| AMM82D | Amphetamine | ✓ | | | |
| AUKY62 | Amphetamine | ✓ | | | |
| B2Y873 | Amphetamine | ✓ | | | |
| BMJ8CX | Amphetamine | ✓ | | | |
| BP6NUH | d-amphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |
| BT9L24 | Amphetamine | ✓ | | | |
| C6TL8W | Amphetamine | ✓ | | | |
| CB3NBD | Amphetamine | ✓ | | | |
| CDMTP3 | Amphetamine | ✓ | | | |
| CT4N6Y | Amphetamine | | 529 | | ng/ml |
| DJTMJX | Amphetamine | ✓ | | | |
| EJPEUB | d-amphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |
| EMPQQB | d-amphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |
| EWB2UB | Amphetamine | ✓ | | | |
| F6LKQF | Amphetamine | ✓ | | | |
| FF8JPX | Amphetamine | ✓ | | | |
| FJ7VLX | Amphetamine | ✓ | | | |
| FXK3FA | Amphetamine | ✓ | | | |

# TABLE 3B: Confirmatory Results - Item 3

| ***What drugs/metabolites were detected in Item 3?*** | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| G3QAED | d-methamphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |
| GFG7GB | d-amphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |
| GRAEFD | No drugs/metabolites detected utilizing confirmatory methods. | | | | |
| GUKA4Q | Amphetamine | ✓ | | | |
| GZP7MQ | amphetamine | | 0,40 | | mg/l |
| HPHQEX | Amphetamine | ✓ | | | |
| HQF42P | Amphetamine | ✓ | | | |
| JQ9FTB | Amphetamine | ✓ | | | |
| KNE3R4 | amphetamine | ✓ | | | |
| KVY39G | No drugs/metabolites detected utilizing confirmatory methods. | | | | |
| L2447P | Amphetamine | ✓ | | | |
| LDU3QZ | Amphetamine | ✓ | | | |
| LDZAZM | Amphetamine | ✓ | | | |
| LERDM3 | Amphetamine | ✓ | | | |
| | Methamphetamine | ✓ | | | |
| LHPWN2 | amphetamine | ✓ | | | |
| LQMJMT | amphetamine | ✓ | | | |
| LYVVX6 | Amphetamine | ✓ | | | |
| M4Q32Y | Amphetamine | ✓ | | | |
| M6VYZ9 | Amphetamine | ✓ | | | |
| M9UBV9 | Amphetamine | ✓ | | | |
| MGR2KP | Amphetamine | ✓ | | | |
| MNWK33 | Amphetamine | | | | |
| MU2CDL | Amphetamine | ✓ | | | |
| MUJMT7 | d-Amphetamine | ✓ | | | |
| | l-Amphetamine | ✓ | | | |
| NK7TCH | Amphetamine | ✓ | | | |

# TABLE 3B: Confirmatory Results - Item 3

| ***What drugs/metabolites were detected in Item 3?*** | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| NYNLZP | No drugs/metabolites detected utilizing confirmatory methods. | | | | |
| P7KZZG | Amphetamine | ✓ | | | |
| PXQTHB | Amphetamine | ✓ | | | |
| Q4EUZ2 | d-amphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |
| Q63FMW | Amphetamine | ✓ | | | |
| QKXQGU | BMPEA/amphetamine | ✓ | | | |
| QQJTDY | Amphetamine | ✓ | | | |
| QXKXCA | amphetamine | ✓ | | | |
| RYRJG2 | No drugs/metabolites detected utilizing confirmatory methods. | | | | |
| TG94UK | Amphetamine | ✓ | | | |
| TLRYZX | d-amphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |
| TMFE6Z | No drugs/metabolites detected utilizing confirmatory methods. | | | | |
| TNT2PY | Amphetamine | ✓ | | | |
| TQFMCV | Amphetamine | ✓ | | | |
| TRTAUA | Amphetamine | ✓ | | | |
| TUGNHJ | amphetamine | | 488 | 23,5 | ng/mL |
| UR8YTF | Amphetamine | ✓ | | | |
| UTH8CZ | amphetamine | ✓ | | | |
| V2AXJT | amphetamine | | 560 | 15% | ug/L |
| VMBUCG | Amphetamine | ✓ | | | |
| VV46MC | Amphetamine | | 418 | 140 | ng/mL |
| WWVHMA | Amphetamine | ✓ | | | |
| X4AVWT | Amphetamine | ✓ | | | |
| XCKWHT | Amphetamine | ✓ | | | |
| XHU9GF | Amphetamine | ✓ | | | |
| XTEFHP | Amphetamine | ✓ | | | |

# TABLE 3B: Confirmatory Results - Item 3

| ***What drugs/metabolites were detected in Item 3?*** | | | | | |
|---|---|---|---|---|---|
| **WebCode** | **Analyte Reported** | **Qualitative Only** | **Reported Concentration** | **Uncertainty** | **Units** |
| XZPYEU | d-amphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |
| YCZT6D | Amphetamine | ✓ | | | |
| YNDT4R | d-amphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |
| YQGNMV | d-amphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |
| Z4ZQF7 | Amphetamine | | 567 | 190 | ng/mL |
| ZBKTMA | Amphetamine | ✓ | | | |
| ZGR6XN | Amphetamine | ✓ | | | |
| ZVQ26T | d-amphetamine | ✓ | | | |
| | l-amphetamine | ✓ | | | |

| **Confirmatory Response Summary for Item 3** | **Participants: 103** |
|---|---|
| Amphetamine: | 96 (93.2%) |
| Other Identified Drugs/Metabolites: | 1 (1.0%) |
| No Drugs/Metabolites Detected Utilizing Confirmatory Methods: | 7 (6.8%) |

# Raw Data - Item 3

TABLE 3C

**Item 3 Raw Data - Amphetamine**
**Preparation concentration: (600 ng/mL)**

| WebCode | List of Raw Data determinations (ng/mL) | | |
|---|---|---|---|
| 7AN9EP | 588.3 | 576.4 | 574.0 |
| 9K27GY | 456.0 | 479.0 | |
| CT4N6Y | 529.7 | | |
| TUGNHJ | 488.0 | | |
| V2AXJT | 554.0 | 572.0 | |
| VV46MC | 418.0 | 447.0 | |
| Z4ZQF7 | 567.0 | 580.0 | |

## Statistical Analysis for Item 3 - Amphetamine

Please note: Statistical analysis has not been provided due to the low number of raw data responses.

# Reporting Procedures - Item 3

TABLE 3D - Item 3

| Quantitative Reporting Procedures | |
|---|---|
| **WebCode** | ***If quantitative analysis was performed, the reported concentrations are:*** |
| 7AN9EP | The mean of duplicate/several determinations. |
| 9K27GY | Lower of the duplicate samples is the concentration reported. |
| CT4N6Y | A single determination. |
| TUGNHJ | A single determination. |
| V2AXJT | The mean of duplicate/several determinations. |
| VV46MC | The lowest of duplicate |
| Z4ZQF7 | Lowest of duplicate sample |

| Response Summary for Item 3 | | Participants: 7 |
|---|---|---|
| A single determination: | 2 (28.6%) | |
| The mean of duplicate/several determinations: | 2 (28.6%) | |
| Other: | 3 (42.9%) | |

# Methods of Analysis - Item 3

TABLE 3E - Item 3

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| 2JBUGR | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | ✓ | ✓ | |
| 3743CY | LC/MS/MS | ✓ | ✓ | |
| 3AZRVQ | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | |
| | GC/MS | ✓ | ✓ | |
| 3RJMAY | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| 43TPZP | LC/MS/MS | ✓ | ✓ | ✓ |
| 4AFBFN | LC-HRMS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| 4AVRBG | Immunoassay | ✓ | | |
| | LC-QTOF | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | LC/MS/MS | | ✓ | |
| 4AYEMP | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| 4ET9KQ | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| 4YW39M | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| 6CGVE9 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| 6M2633 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| 6XECWG | Immunoassay | ✓ | | |
| 76V339 | Immunoassay | ✓ | | |
| 7AN9EP | LC/MS | | ✓ | |
| 7TJU33 | LC-QTOF | | ✓ | |
| | GC/MS | | ✓ | |
| 83PYUJ | High resolution accurate mass | ✓ | | |
| | GC/MS | | ✓ | |
| 8J9TG2 | Immunoassay | ✓ | | |
| | LC-QTOF | | ✓ | |
| 8WWUYT | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |

# TABLE 3E: Methods of Analysis - Item 3

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| 96RG6J | Immunoassay | ✓ | | |
| | LC/MS | | ✓ | |
| | GC/MS | | ✓ | |
| 98BFDM | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| 9K27GY | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| 9N397Z | Immunoassay | ✓ | | |
| 9PUCTF | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| A4APRT | LC/MS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| A7X4G3 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| A87HGG | Immunoassay | ✓ | | |
| AF6VNC | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| AFYTRC | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| ALQUEK | Immunoassay | ✓ | | |
| | LC/MS | ✓ | ✓ | |
| | GC/MS | ✓ | ✓ | |
| AMM82D | LC/MS/MS | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| AUKY62 | GC/MS | | ✓ | |
| B2Y873 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| BDRNV4 | Immunoassay | ✓ | | |
| BMJ8CX | Immunoassay | ✓ | | |
| | LC-QTOF | | ✓ | |
| BP6NUH | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | |
| | GC/MS | | ✓ | |
| BT9L24 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| C6TL8W | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC-QTOF | | ✓ | |
| CB3NBD | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |

 

# TABLE 3E: Methods of Analysis - Item 3

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| CDMTP3 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| CT4N6Y | Immunoassay | ✓ | | |
| | Orbitrap-LC/MS | ✓ | | |
| | LC/MS/MS | | ✓ | ✓ |
| DJTMJX | LC/MS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| | Rapid Chromatographic Immunoassay | ✓ | | |
| EJPEUB | GC/MS | | ✓ | |
| | LC/HRMS | ✓ | ✓ | |
| EMPQQB | GC/MS | | ✓ | |
| | HRMS | ✓ | | |
| EPD7WD | Immunoassay | ✓ | | |
| EWB2UB | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| F6LKQF | LC/MS/MS | | ✓ | |
| | GC/MS | ✓ | ✓ | |
| FF8JPX | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| FJ7VLX | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| FXK3FA | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| | GC/NPD | ✓ | | |
| G3QAED | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS | | ✓ | |
| GFG7GB | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | |
| | GC/MS | | ✓ | |
| GRAEFD | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| GUKA4Q | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| GZLQ96 | Immunoassay | ✓ | | |
| GZP7MQ | LC/MS/MS | | | |
| HBLHEA | Immunoassay | ✓ | | |
| HPHQEX | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |

# TABLE 3E: Methods of Analysis - Item 3

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| HQF42P | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| JQ9FTB | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| KNE3R4 | LC/MS/MS | ✓ | ✓ | |
| KVY39G | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| L2447P | LC/MS/MS | ✓ | ✓ | |
| LDU3QZ | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| LDZAZM | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| LERDM3 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| LHPWN2 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| LQMJMT | LC/MS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| LX6WJ7 | GC/MS | ✓ | | |
| LYVVX6 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| M4Q32Y | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | |
| M6VYZ9 | LC/MS/MS | ✓ | | |
| | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| M9UBV9 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LCQTOF | | ✓ | |
| MGR2KP | LC/MS/MS | ✓ | ✓ | |
| MNWK33 | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| MU2CDL | Immunoassay | ✓ | | |
| | LC-QTOF | | ✓ | |
| | GC/MS | | ✓ | |
| MUJMT7 | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| NK7TCH | LC/MS/MS | ✓ | ✓ | |
| NYNLZP | GC/MS | ✓ | ✓ | |

# TABLE 3E: Methods of Analysis - Item 3

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| P7KZZG | LC/MS/MS | ✓ | ✓ | |
| PG4AQV | Immunoassay | ✓ | | |
| | GC/MS | ✓ | | |
| PXQTHB | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| Q4EUZ2 | LC-HRMS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| Q63FMW | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| QKXQGU | LC-QTOF-MS | ✓ | | |
| | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| QQJTDY | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| QXKXCA | LC/MS/MS | ✓ | ✓ | |
| RDB8PZ | Immunoassay | ✓ | | |
| RQLHHW | GC/FID | | ✓ | ✓ |
| | Immunoassay | ✓ | | |
| RYRJG2 | GC/MS | ✓ | ✓ | |
| TG94UK | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| TLRYZX | LC-HRMS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| TMFE6Z | Immunoassay | ✓ | | |
| TNT2PY | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| TQFMCV | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| TRTAUA | GC/MS | ✓ | ✓ | |
| | Immunoassay | ✓ | | |
| TUGNHJ | LC/MS/MS | ✓ | | |
| | GC/MS | | ✓ | ✓ |
| | LC/HRMS | ✓ | | |
| UR8YTF | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| UTH8CZ | LC/MS/MS | ✓ | ✓ | |
| UY9DEG | Immunoassay | ✓ | | |

# TABLE 3E: Methods of Analysis - Item 3

| WebCode | Method | Screening | Confirmatory | Quantitation |
|---|---|---|---|---|
| V2AXJT | GC/MS | ✓ | | |
| | LC/MS | ✓ | | |
| | Immunoassay | ✓ | | |
| | LC/MS/MS | | | ✓ |
| VMBUCG | GC/MS | | ✓ | |
| VV46MC | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| WWVHMA | LC/MS/MS | ✓ | ✓ | |
| X4AVWT | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| XCKWHT | Immunoassay | ✓ | | |
| | GC/MS | ✓ | ✓ | |
| XHU9GF | LC/MS | ✓ | ✓ | |
| XTEFHP | LC/MS/MS | ✓ | ✓ | |
| | Immunoassay | ✓ | | |
| XZPYEU | LC-HRMS/MS | ✓ | | |
| | GC/MS | | ✓ | |
| YCZT6D | GC/MS | | ✓ | |
| YNDT4R | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | ✓ | ✓ | |
| YQGNMV | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | |
| | GC/MS | | ✓ | |
| Z4ZQF7 | Immunoassay | ✓ | | |
| | LC/MS/MS | | ✓ | |
| ZBKTMA | Immunoassay | ✓ | | |
| | LC-QTOF | | ✓ | |
| ZGR6XN | Immunoassay | ✓ | | |
| | GC/MS | | ✓ | |
| | LC/MS/MS | | ✓ | |
| ZVQ26T | Immunoassay | ✓ | | |
| | LC/MS/MS | ✓ | ✓ | |
| | GC/MS | ✓ | ✓ | |

 

| Response Summary for Item 3 - Methods of Analysis | | | Participants: 116 |
|---|---|---|---|
| | **Screening** | **Confirmatory** | **Quantitation** |
| **Immunoassay:** | 83 | 0 | 0 |
| **GC/MS:** | 30 | 75 | 1 |
| **LC/MS:** | 3 | 5 | 0 |
| **LC/MS/MS:** | 25 | 36 | 4 |
| **Other:** | 13 | 9 | 1 |

 

# Additional Comments for Item 3

TABLE 3F

| WebCode | Item Comments |
|---|---|
| 3AZRVQ | Internal standard used include Mepivacaine |
| 3RJMAY | There was a significant Caffeine peak identified in the sample. |
| 43TPZP | Drugs included in panel: Cyclobenzaprine, Imipramine, MDPV, Meperidine, Mitragynine, Normeperidine, Phencyclidine, Quetiapine, and Zolpidem. |
| 4AFBFN | internal standards: mepivacaine, mephobarbital (screen) internal standards: mepivacaine, nalorphine (confirmation) |
| 4AYEMP | internal standard: mepivacaine |
| 4ET9KQ | mepivacaine was the internal standard used for all analytes. |
| 83PYUJ | Internal standard: mepivacaine |
| 8WWUYT | n-Propylamphetamine, Mepivacaine, and Hexobarbital used as internal standards. |
| 96RG6J | Mepivacaine used as internal standard |
| 98BFDM | Internal Standard used was MDA-D5 |
| 9K27GY | Deuterated standards are used for compounds we can quantitate. Our lab is currently only able to quantitate samples that could contain basic drugs or cannabinoids. I have included the list of drugs the lab can quantitate or qualitatively identify: Amphetamine, Methamphetamine, MDA, MDMA, Ketamine, Mescaline (Qualitatively only), Phentermine, Diphenhydramine, LSD, Psilocin (qualitatively only), Ephedrine/Pseudoephedrine (qualitatively only), THC-OH, THC, THC-COOH |
| A7X4G3 | * Internal standard: flurazepam / estazolam. * Sample preparation: L/L extraction. * The final extraction is derivatized with BSTFA and injected by GC-MS. * LOD amphetamine: 400 ng/mL. |
| A87HGG | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL. |
| AF6VNC | Fluconazole indicated by GCMS. Not confirmed or reported. |
| DJTMJX | Alere iCassette (THC) test device was used to screen for THC, referred to in 3-5 as rapid chromatographic immunoassay. The cutoff concentration for the assay is 50 ng/mL. |
| EMPQQB | Internal standards: Mepivacaine/Mephobarbital (HRMS) and Mepivacaine/Naloprhine (GCMS) |
| EPD7WD | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL. |
| EWB2UB | Spectra was identified with ions associated with Ephedrine/Pseudoephedrine. Neither of these analytes are on the laboratory's drug panel and could not be reported. |
| G3QAED | mepivacaine was used as an internal standard. |
| GFG7GB | Internal standard used was mepivacaine. |
| GRAEFD | Internal Standards 1. SKF-525A 2. Hexobarbital |
| GUKA4Q | ELISA Benzodiazepines cut-off set at 10ng/mL. ELISA Benzodiazepines screened at 114 (slightly positive). LC/MS/MS confirmation for benzodiazepines was negative. |
| HBLHEA | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL. |

 

# TABLE 3F: Additional Comments for Item 3

| WebCode | Item Comments |
|---|---|
| HQF42P | Confirmatory ISTD: NPA and SKF |
| KNE3R4 | Note: samples are not screened by an immunoassay screening method. All screening and confirmation conducted by LCMS |
| L2447P | Internal standard: Flurazepam. LoD: 10 ng/mL. |
| LDU3QZ | Phenyltoloxamine |
| M4Q32Y | Amphetamines cutoff on immunoassay (EMIT) is 1000, sample deflected. LOQ for amphetamine is 25 ng/mL Deuterated IS |
| MU2CDL | IS used in QTOF analyses: Fentanyl-D5, Imipramine-D3, MDMA-D5, Methaqualone-D7, and Triazolam-D4. Caffeine, Ephedrine/Pseudoephedrine, and Fluconazole disregarded. |
| MUJMT7 | Internal standard utilized was mepivacaine. Amphetamine was derivatized with (S)-(-)-N-(trifluoroacetyl)- prolyl chloride for GCMS analysis. |
| NK7TCH | Amphetamine-d11 ISTD; LOD 5ng/ml |
| P7KZZG | Amphetamine: ISTD: Amphetamine-d11; LOD: 5 ng/mL |
| PG4AQV | The sample was first screened using an immunoassay method. This immunoassay method only screens for the following drugs/drug classes: Amphetamines, Benzodiazepines, Cannabinoids, Cocaine, Opiates, and PCP. A GC/MS scan was used as a secondary screening method. |
| PXQTHB | N-Propylamphetamine, Mepivacaine, and Hexobarbital were used as Internal Standards. |
| Q4EUZ2 | For LC-HRMS/MS testing, mepivacaine and mephobarbital were used as internal standards. For GC/MS testing, mepivacaine and nalorphine were used as internal standards |
| Q63FMW | The cut off of amphetamine is 50 ng/mL |
| QKXQGU | BMPEA and amphetamine cannot be distinguished by the methods used. |
| QXKXCA | ephedrine/pseudoephedrine detected in confirmation method- not reported as per provider- "verification testing showed low levels of ephedrine, fluconazole and pseudoephedrine in all three samples, please disregard these...." |
| RDB8PZ | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL. |
| RQLHHW | GC/FID for Alcohol confirmation - LLQ 20mg/dL - report less than 20mg/dL |
| TMFE6Z | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL. |
| TQFMCV | Codeine-D3 and methamphetamine-D9 are used as internal standards |
| TRTAUA | Screening GC/MS internal standards were Mepivacaine, Methohexital, and Nalorphine-diTMS. Confirmatory GC/MS internal standard was Amphetamine-D11. |
| UY9DEG | Analytes tested for and cutoffs provided below: Fentanyl 2 ng/ml, AB-Pinaca 2.5 ng/ml, Methamphetamine 200 ng/ml, Barbs 200 ng/ml, Benzos 150 ng/ml, Methadone 300 ng/ml, Opiates 200 ng/ml, Creatinine 20 mg/dl, Benzoylecgonine 150 ng/ml, Oxycodone 50 ng/ml, Tramadol 5 ng/ml, THC 20 ng/ml, TCA 150 ng/ml, Amphetamine 200 ng/ml, Buprenorphine 1 ng/ml, 6-mam 10 ng/ml, JWH-018 20 ng/ml, alpha-PVP 5 ng/ml, UR-144 10 ng/ml |
| V2AXJT | quantification ISD d5-amphetamine |
| WWVHMA | Amphetamine-d11, LOD 5 ng/mL |

 

# TABLE 3F: Additional Comments for Item 3

| WebCode | Item Comments |
|---|---|
| XHU9GF | Estazolam was used as internal standard. |
| XZPYEU | IS: mepivacaine, mephobarbital |
| YCZT6D | Internal standard: Flurazepam. |
| YNDT4R | mepivacaine was used as an retention time internal standard. Caffeine not reported. |
| YQGNMV | Mepivacaine used as internal standard |
| ZGR6XN | Codeine-D3 and Methamphetamine-D9 are used as internal standards |
| ZVQ26T | Internal standard: mepivacaine |

# Additional Test Comments

TABLE 4

| WebCode | Additional Comments |
|---|---|
| 43TPZP | Drugs included in panel: Cyclobenzaprine, Imipramine, MDPV, Meperidine, Mitragynine, Normeperidine, Phencyclidine, Quetiapine, and Zolpidem. |
| 9K27GY | Deuterated standards are used for compounds we can quantitate. Our lab is currently only able to quantitate samples that could contain basic drugs or cannabinoids. I have included the list of drugs the lab can quantitate or qualitatively identify: Amphetamine, Methamphetamine, MDA, MDMA, Ketamine, Mescaline (Qualitatively only), Phentermine, Diphenhydramine, LSD, Psilocin (qualitatively only), Ephedrine/Pseudoephedrine (qualitatively only), THC-OH, THC, THC-COOH. |
| A7X4G3 | No data. |
| A87HGG | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL. |
| EPD7WD | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL. |
| F6LKQF | samples delivered by UPS were not cold or refrigerated |
| HBLHEA | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL. |
| LYVVX6 | Only tested for drugs that are included on the [Laboratory] drug panel. |
| M4Q32Y | There could be some improvements to data entry, this was a cumbersome way to enter data. |
| RDB8PZ | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL. |
| TMFE6Z | All substances detected using immunoassay testing, cutoffs are listed below. 6AM- 10 ng/mL, AMP- 1,000 ng/mL, BNZ- 200 ng/mL, COC- 300 ng/mL, CR- 20 mg/dL, THC- 50 ng/mL, OPI- 300 ng/mL, OXY- 100 ng/mL, FEN- 1 ng/mL. |
| XZPYEU | possible contaminates found: pseudoephedrine, fluoxetine |
| YNDT4R | Thank you for clearly stating drugs that are part of the matrix, rather than PT targets. |

-End of Report-
(Appendix may follow)

**Collaborative Testing Services ~ Forensic Testing Program**

# Test No. 22-5671: Urine Drug Analysis

DATA MUST BE SUBMITTED BY **May 16, 2022, 11:59 p.m.** TO BE INCLUDED IN THE REPORT

Participant Code: U1234J WebCode: 2AJDRN

**Scenario:**

Investigators have submitted three urine specimens from three separate cases for your analysis. Using your laboratory's procedures, analyze each sample and report the presence of any drugs and/or metabolites.Case 1: A 26-year-old male was subject to a routine drug test as part of a drug and alcohol rehabilitation program. A urine sample was collected for analysis.Case 2: A 30-year-old male was pulled over for swerving in between lanes. He was driving alone and seemed confused and drowsy. A urine sample was collected for analysis an hour after the incident had occurred. Case 3: A 17-year-old female high school student receiving an annual physical complained of being tired. She reported extreme mood swings and insomnia. A urine sample was collected for analysis.

*-Verification testing showed low levels of ephedrine, fluconazole and pseudoephedrine in all three samples, please disregard these as well as artifacts of production, methanol and acetonitrile.*

***PLEASE NOTE** The purpose of this test is the examination of drugs listed in section 1308 of Title 21 Code of Federal Regulations under the United States Controlled Substances Act that fall into the following classes: benzodiazepines, nonbenzodiazepine hypnotics (z-drugs), barbiturates, opioids, illicit hallucinogens, illicit stimulants, illicit depressants, and cannabinoids. Please test accordingly.*

**Items Submitted (Sample Pack UDRG):**

Item 1: Urine sample from Case 1
Item 2: Urine sample from Case 2
Item 3: Urine sample from Case 3

## Screening Results for Item 1:

**1-1). Please indicate the screening results for Item 1.**

- ○ No drugs detected utilizing screening methods.
- ○ Drug(s) detected (list each class and/or drug name below).

## Confirmatory Results for Item 1:

**1-2). Was confirmatory analysis performed for this item?** ○ Yes ○ No

**1-3). What drugs/metabolites were detected in Item 1? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.**

☐ No drugs/metabolites detected utilizing confirmatory methods.

| Analyte | Qualitative Only? | Reported Concentration | Uncertainty | Units |
|---|---|---|---|---|
| | ☐ | | | ( ) |

**Date(s) Analysis Performed on Analyte:**

**Raw Data (ng/mL):**

| | | | | | |
|---|---|---|---|---|---|
| | | | | | |

**1-4). If quantitative analysis was performed, are the reported concentrations above**

- ○ A single determination?
- ○ The mean of duplicate / several determinations?
- ○ Other? (Specify):

**1-5). Please select the analysis method(s) performed and check whether it was used for screening, confirmatory testing, and/or quantitation.**

**Please list each method only once.**

| Method Used | Screening | Confirmatory | Quantitation |
|---|---|---|---|
| | ☐ | ☐ | ☐ |

**1-6). Additional Comments for Item 1**

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

***Please note:*** *Any additional formatting applied in the free form space below will not transfer to the Summary Report and may cause your information to be illegible. This includes additional spacing and returns that present your responses in lists and tabular formats.*

## Screening Results for Item 2:

**2-1). Please indicate the screening results for Item 2.**

- ○ No drugs detected utilizing screening methods.
- ○ Drug(s) detected (list each class and/or drug name below).

## Confirmatory Results for Item 2:

**2-2). Was confirmatory analysis performed for this item?** ○ Yes ○ No

**2-3). What drugs/metabolites were detected in Item 2? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.**

☐ No drugs/metabolites detected utilizing confirmatory methods.

| Analyte | Qualitative Only? | Reported Concentration | Uncertainty | Units |
|---|---|---|---|---|
| | ☐ | | | ( ) |

**Date(s) Analysis Performed on Analyte:**

**Raw Data (ng/mL):**

| | | | | | |
|---|---|---|---|---|---|
| | | | | | |

**2-4). If quantitative analysis was performed, are the reported concentrations above**

- ○ A single determination?
- ○ The mean of duplicate / several determinations?
- ○ Other? (Specify):

**2-5). Please select the analysis method(s) performed and check whether it was used for screening, confirmatory testing, and/or quantitation.**

**Please list each method only once.**

| Method Used | Screening | Confirmatory | Quantitation |
|---|---|---|---|
| | ☐ | ☐ | ☐ |

**2-6). Additional Comments for Item 2**

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

***Please note:*** *Any additional formatting applied in the free form space below will not transfer to the Summary Report and may cause your information to be illegible. This includes additional spacing and returns that present your responses in lists and tabular formats.*

## Screening Results for Item 3:

**3-1). Please indicate the screening results for Item 3.**

- ○ No drugs detected utilizing screening methods.
- ○ Drug(s) detected (list each class and/or drug name below).

## Confirmatory Results for Item 3:

**3-2). Was confirmatory analysis performed for this item?** ○ Yes ○ No

**3-3). What drugs/metabolites were detected in Item 3? If quantitative determinations were performed, please record raw data in the provided spaces in ng/mL.**

☐ No drugs/metabolites detected utilizing confirmatory methods.

| Analyte | Qualitative Only? | Reported Concentration | Uncertainty | Units |
|---|---|---|---|---|
| | ☐ | | | ( ) |

**Date(s) Analysis Performed on Analyte:**

**Raw Data (ng/mL):**

| | | | | | |
|---|---|---|---|---|---|
| | | | | | |

**3-4). If quantitative analysis was performed, are the reported concentrations above**

- ○ A single determination?
- ○ The mean of duplicate / several determinations?
- ○ Other? (Specify):

**3-5). Please select the analysis method(s) performed and check whether it was used for screening, confirmatory testing, and/or quantitation.**

**Please list each method only once.**

| Method Used | Screening | Confirmatory | Quantitation |
|---|---|---|---|
| | ☐ | ☐ | ☐ |

**3-6). Additional Comments for Item 3**

Please include any relevant information such as internal standard(s) used, limits of detection, etc.

***Please note:*** *Any additional formatting applied in the free form space below will not transfer to the Summary Report and may cause your information to be illegible. This includes additional spacing and returns that present your responses in lists and tabular formats.*

**Date Samples Received:**

## Additional Comments on Test

***Please note:*** *Any additional formatting applied in the free form space below will not transfer to the Summary Report and may cause your information to be illegible. This includes additional spacing and returns that present your responses in lists and tabular formats.*

# RELEASE OF DATA TO ACCREDITATION BODIES

**The Accreditation Release is accessed by pressing the "Continue to Final Submission" button online and can be completed at any time prior to submission to CTS.**

**CTS submits external proficiency test data directly to ASCLD/LAB, ANAB, and/or A2LA. Please select one of the following statements to ensure your data is handled appropriately.**

○ This participant's data is intended for submission to ASCLD/LAB, ANAB, and/or A2LA. (Accreditation Release section below must be completed.)
○ This participant's data is **not** intended for submission to ASCLD/LAB, ANAB, and/or A2LA.

Have the laboratory's designated individual complete the following steps
**only if your laboratory is accredited in this testing/calibration discipline**
by one or more of the following Accreditation Bodies.

**Step 1: Provide the applicable Accreditation Certificate Number(s) for your laboratory**

**ANAB** Certificate No.
(Include ASCLD/LAB Certificate here)

**A2LA** Certificate No.

**Step 2: Complete the Laboratory Identifying Information in its entirety**

Authorized Contact Person and Title

Laboratory Name

Location (City/State)